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ABSTRACT 
Cysteinyl residues in proteins are important for many cellular processes and 
unregulated modification of the cysteine thiol group can have negative effects on cell 
vitality and viability. In this thesis, the potential for use of the isotope coded affinity tag 
(ICAT) method for detection of cysteine modification has been investigated. ICAT 
reagents label free cysteine thiols.  The aim of this study was to use HL-60 cells treated 
with gliotoxin, a fungal metabolite with a reactive disulfide bridge, as a system to 
evaluate the performance of ICAT for identification of cysteine modification in a whole 
cell proteome. Gliotoxin has antimicrobial, antitumor, immunosuppressive and cytotoxic 
properties that have been related to cysteine modification in proteins. Cellular assays 
including  viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, cell 
cycle analysis,  and measurement of reactive oxygen species using dichlorofluorescin 
diacetate were  used to establish conditions for measuring the effects of gliotoxin on 
HL-60 cells prior to large-scale cellular damage. Cells exposed to gliotoxin and control 
cells were then labeled with ICAT reagents and analysed by offline reversed phase liquid 
chromatography followed by matrix-assisted laser desorption/ionization tandem mass 
spectrometry. The pilot results identified tubulin, glyceraldehyde-3-phosphate 
dehydrogenase and peptidyl-prolyl cis-trans isomerase as putative targets of gliotoxin. 
Additionally, this study showed that ICAT can be used to detect modified cysteines from 
a highly complex sample, but further optimization is needed to unlock the full potential 
for detection of cysteine modification in complex samples. 
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ABBREVATIONS 
ACN acetonitrile 
ADH alcohol dehydrogenase 
BSA bovine serum albumin 
CHCA α-cyano-4-hydroxycinnamic acid 
CK creatin kinase 
cys cysteine/cysteines 
DAPI 4',6-diamidino-2-phenylindole 
DCFDA 2’,7’-Dichlorofluorescin diacetate  
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DTT dithiothreitol 
ETP epipolythiodioxopiperazine 
FCS fetal calf serum 
FDR false discovery rate 
FTase farnesyltransferase 
GRx glutaredoxin 
GSH glutathione 
GSSG Glutathione disulfide 
GTX gliotoxin 
ICAT isotope coded affinity tag 
LC liquide chromatografie 
MALDI matrix-assisted laser desorption/ionization 
MS mass spectrometer/spectrometry 
MS/MS tandem mass spectrometry 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NF-κB nuclear factor-κB 
PBS phosphate buffered solution 
RNS reactive nitrogen species 
ROS reactive oxygen species 
RP-LC reversed phase liquid chromatography 
RPMI Roswell Park Memorial Institute medium 
SDS sodium dodecyl sulfate 
TFA trifluoroacetic acid 
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1 Introduction 
Plants, fungi and microbes produce a large variety of small molecules including 
those secreted as toxins that can affect a range of cellular processes such as 
transcription, development and intercellular communication. These secondary 
metabolites are often of therapeutic interest as they can be used directly or as lead 
compounds for new drugs. One well-known secondary metabolite is penicillin, a potent 
antibiotic agent. The fungal metabolite gliotoxin (GTX) was discovered soon after 
penicillin and has a wide range of effects. 
GTX was first isolated in 1936 from Trichoderma sp. (previously named Gliocladium 
fimbriatum; Weindling and Emerson, 1936). Subsequently gliotoxin was found in other 
fungi including Aspergillus fumigatus, Aspergillus chevalieri, Penicillum obscurum and 
Trichderma viride (Brian and Hemming, 1945; Wilkinson and Spilsbury, 1965).  
Gliotoxin is a member of the epipolythiodioxopiperazine (ETP) class of molecules. 
This class consists of at least 14 members and is characterized by a disulfide bridged 
diketopiperazine ring (Gardiner, Waring and Howlett, 2005). The sulfur-bridged ring is 
essential for the effects of ETPs on cells, bacteria and viruses (Okamoto et al., 1986) and 
chemical modification of the sulfurs leads to complete loss of biological activity.  
GTX has antibacterial, antifungal, antitumor, antiviral and immunosuppressive 
properties and inhibits mammalian cell proliferation (Jordan and Cordiner, 1987; 
Gardiner, Waring and Howlett, 2005). The exact mechanism of action is unknown but 
there are two main hypotheses (Jordan and Cordiner, 1987): (1) the ETP sulfurs bind 
covalently to cysteine sulfurs in proteins forming mixed disulfides that may affect the 
activity of modified proteins (Srinivasan et al., 2006), and/or (2) by cycling between the 
oxidized and reduced forms of ETPs with generation of the reactive oxygen species 
superoxide, hydrogen peroxide and hydroxyl radical (Munday, 1982). 
 
1.1 Structure and biosynthesis of gliotoxin 
The secondary metabolite gliotoxin contains the typical ETP sulfur-bridged 
diketopiperazine (Fig. 1). Biosynthesis of GTX starts with two amino acids, phenylalanine 
and serine (Suhadolnik and Chenoweth, 1958; Gardiner and Howlett, 2005). The discovery 
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of a gene cluster related to the 
biosynthesis of another ETP sirodesmin in 
Leptosphaeria maculans allowed the 
prediction of a similar cluster for gliotoxin 
in Aspergillus fumigatus (Gardiner et al., 
2004; Gardiner and Howlett, 2005). This 
cluster consists of 12 different genes (gli 
genes): gliA, gliC, gliF, gliG, gliI-K, gliM, gliN, 
gliP, gliT and gliZ (Gardiner and Howlett, 
2005). The predicted biosynthetic pathway starts with serine and phenylalanine which 
are condensed by a non-ribosomal peptide synthetase (GliP) producing the 
diketopiperazine cyclo-(L-phenylalanyl-L-seryl) core (Gardiner and Howlett, 2005; Fox and 
Howlett, 2008). A cytochrome P450 oxidoreductase (GliC) activates the core prior to 
addition of glutathione by a glutathione S-tranferase (GliG), yielding a bis(glutathione) 
adduct (Scharf et al., 2011; Chang et al., 2013). A dipeptidase (GliJ) and a thioesterase (GliI) 
cleave the glutathione residues leaving two thiol groups. Subsequently, a methyl 
transferase (GliN) adds a methyl group to the molecule and one of the cytochrome P450 
monooxogenases (GliC or GliF) closes the ring between the benzyl and the 
diketopiperazine ring. Finally, a thioredoxin reductase leads to the formation of the 
disulfide bond. Most of the genes are regulated by a zinc-finger transcription factor (GliZ) 
and the product gets transported out of the cell by a major facilitator type transporter 
(GliA; Bok et al., 2006; Scharf et al., 2010). Two proteins, GliT and GliK, protect the fungi 
against the toxin (Scharf et al., 2010; Schrettl et al., 2010; Gallagher et al., 2012).  
 
1.2 Toxic effects of gliotoxin on mammalian cells 
Many cellular effects of GTX have been investigated since its discovery, but there 
are very few instances in which the specific molecular interactions of GTX are described. 
There are a variety of actions on cultured mammalian cells including apoptotic cell death 
(Peterson et al., 2010; Witko-Sarsat et al., 2010; Speth et al., 2011; Tartakovsky et al., 2012; 
Hubmann et al., 2013) and  depletion of mature lymphocytes (Mullbacher et al., 1988). 
GTX caused 50% cell loss at 0.5 µM and 0.03 µM respectively in A549 (human lung 
Figure 1: Structure of gliotoxin. 
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carcinoma epithelia cell line) and NR8383 (rat alveolar macrophage cell line) cells. GTX 
induced apoptosis in cultured hepatic stellate cells at 1.5 μM, and in hepatic stellate cells 
in mice dosed at 3 mg/kg (Hartland et al., 2009; Shen et al., 2011). The cytotoxicity in 
hepatic stellate cells may be due to increased mitochondria permeability resulting in 
cytochrome c release and activation of caspase-3 (Wright et al., 2001; Kweon et al., 2003). 
Shortly after GTX treatment, the cells showed an induced activity of caspase 3 and DNA 
fragmentation (DNA laddering), characteristic for apoptosis (Arends, Morris and Wyllie, 
1990). Rat hepatocytes were only affected at a 10 to 100-fold higher concentration of GTX 
and showed necrosis (Wright et al., 2001). 
The nuclear factor NF-kappa B (NF-κB) seems to play a role in immunosuppression 
and apoptosis induced by GTX. GTX inhibits activation of NF-κB in many, but not all, cells 
(Wright et al., 2001; Cho et al., 2009; Trebec-Reynolds et al., 2010; Rashmi et al., 2011). 
Normally, NF-κB is activated by phosphorylation and ubiquitination following 
degradation of the physiological inhibitor IκB-α (Henkel et al., 1993; Traenckner, Wilk and 
Baeuerle, 1994; Napetschnig and Wu, 2013). These post translational modifications 
expose the nuclear localization signal of NF-κB, allowing it to enter the nucleus and bind 
to DNA. Inhibition of NF-κB activation by GTX is suggested to be due to decreased 
degradation of IκB-α by blocking the proteolytic activity of the proteasome (Pahl et al., 
1996b; Kroll et al., 1999). GTX targets the 20S subunit of the proteasome, and 10 mM 
dithiothreitol (DTT) could fully restore the function of the proteasome. This suggests that 
GTX covalently binds to or near the active site of the 20S subunit. NF-κB has important 
roles in immune and inflammatory processes (Napetschnig and Wu, 2013) and inhibition 
by GTX may account for at least some of the immunosuppressive properties of GTX (Pahl 
et al., 1996a). 
Another target might be the mitochondrial permeability transition pore. This pore 
consists of the voltage-dependent anion channel, the adenine nucleotide translocase and 
a peptidyl-prolyl cis-trans isomerase cyclophilin D which is the target of the 
immunosuppressive cyclosporine A.  This pore allows molecules smaller than 1500 Da to 
pass under specific circumstances (Bernardi, 2013) and an increased permeability can lead 
to mitochondrial swelling and cell death via apoptosis or necrosis, depending on the 
conditions (Crompton, 1999). The specific condition for the mitochondrial permeability 
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transition pore to open are oxidative stress, high levels of mitochondrial calcium and low 
levels of ATP (Bernardi, 2013). GTX causes calcium release from rat skeletal and liver 
mitochondria (Schweizer and Richter, 1994; Silva, Winterhalter and Richter, 1997) leading 
to the activation of the mitochondrial permeability transition pore and subsequently to 
apoptosis or necrosis. Supporting this hypotheses, a calcium chelator, quin-2-am, 
prevented DNA laddering in GTX-treated hepatic stellate cells (Wright et al., 2001). 
Additionally, a mitochondrial permeability transition pore inhibitor, tamoxifen, is also 
able to prevent DNA laddering (Wright et al., 2001). Also relevant is the activity of 
cyclosporin A that binds to cyclophilin D and prevents the mitochondrial permeability 
transition pore from opening. However in the presence of GTX cyclosporine A was unable 
to prevent DNA laddering caused by the opening of the mitochondrial permeability 
transition pore. Wright et al. (2001) suggested that GTX may bind to cyclophilin D or other 
mitochondrial permeability transition pore proteins and thereby blocks binding of 
cyclosporine A. 
Some evidence also points to GTX as a NOTCH2 inhibitor (Hubmann et al., 2013). 
NOTCH2 is a receptor in the Notch signal transduction pathway which is linked to many 
processes, for example lineage specification and homeostasis (Artavanis-Tsakonas, Rand 
and Lake, 1999; Miele, 2006). The inhibition of NOTCH2 by GTX leads to apoptosis in 
chronic lymphocytic leukemia cells. In contrast, NF-κB is not inhibited in these cells and 
the GTX treatment leads to an up-regulation of NOTCH3 and NR4A1 (Hubmann et al., 
2013). NR4A1 is involved in the negative selection of self-reactive lymphocytes and is 
induced by a broad range of apoptotic stimuli (Li et al., 2000). 
GTX affects histones by facilitating phosphorylation of histone H3 in murine 
thymocytes treated with 1 μM GTX, likely due to modification of protein kinase A activity 
(Waring, 1997). The phosphorylation of histone H3 may then lead to DNA fragmentation 
and apoptosis. The treated cells were sensitive to micrococcal nuclease and DNase I 
digestion suggesting a relationship between histone H3 phosphorylation and DNA 
fragmentation. A protein kinase A inhibitor, genistein, prevented histone 
phosphorylation and apoptosis in GTX treated thymocytes. GTX has been shown to 
inhibit histone methyltransferase G9a, which introduces methylation on lysine 9 of 
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histone H3 (Sun et al., 2012). An inhibition of G9a can lead to centrosome disruption 
chromosome instability (Kondo et al., 2008). 
Another postulated mode of action of ETPs including GTX is production of reactive 
oxygen species (ROS) by reduction and reoxidation of the disulfide bridge. Bernardo et 
al. (2003) reported that GTX in its oxidized form rapidly enters cells and is reduced by 
cellular GSH to GTX dithiol which is cell-impermeant, leading to accumulation with an up 
to 1000 times increased intracellular concentration of GTX. It has been suggested that in 
the presence of an appropriate reductant such as reduced glutathione (GSH) ETP 
disulfides are reduced to dithiols which can auto-oxidize back to disulfides, converting 
oxygen (O2) into superoxide radical (O2
-) (Eichner et al., 1988; Waring and Beaver, 1996) 
that can give rise to other reactive oxygen species including hydrogen peroxide and 
hydroxyl radical. In some cells the cytotoxic effects of GTX seem to be dependent on ROS 
production (Zhou et al., 2000; Suen et al., 2001). In contrast, Yoshida, Abe and Tsunawaki 
(2000) reported that GTX protected against superoxide production in activated 
neutrophils. 
Spleen cells treated with GTX showed genomic DNA indicative of oxidative stress 
(Braithwaite et al. 1987). Briefly, ROS introduces single-strand breaks in the DNA double-
strand. A plasmid can be present in three different forms: a covalently closed circular 
without any breaks, an open circular with a single-strand break and a linear form with a 
double-strand break. In the present of a suitable reductant GTX damaged cellular and 
plasmid DNA via superoxide production in a cell-free systems (Eichner et al., 1988). 
Plasmid DNA incubated with 0.3 mM GTX and 0.2 mM reductant (GSH or DTT) for 10 min 
resulted in a reduction of the covalently closed circular form to 14% and 17%. The genomic 
DNA treated with 90 μM GTX and 3mM GSH showed extensive laddering after 15 min 
incubation. 
 
1.3 Mechanism of GTX interaction with proteins  
Inhibition of the enzyme farnesyltransferase (FTase) by GTX was discovered in a 
screen for antibiotic activity. Partially purified human FTase was completely inhibited by 4 
μM GTX (IC50 1.1 μM). A GTX derivative in which the sulfurs were alkylated was much less 
active. Reducing conditions (4 mM DTT) were necessary for measurement of FTase, even 
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in the absence of GTX (Vanderpyl et al., 1992). The prevalent oxidation state of GTX in this 
experiment was therefore reduced, suggesting that the dithio structure was involved for 
inhibition of FTase, which is in contrast to the antimicrobial activity requiring the disulfide 
(Cavallito, Bailey and Warner, 1946). FTases are involved in the Ras pathway and thereby 
important for cell survival and proliferation (Lane and Beese, 2006). An in vivo study 
confirmed GTX as an FTase inhibitor and showed antitumor effects on breast cancer cells 
(Vigushin et al., 2004). Human FTase contains two cysteinyl residues (327 and 341) that 
might be modified by direct interaction with GTX or by ROS  
The enzyme glutaredoxin (GRx) is inhibited by GTX and other ETPs through binding 
to an active site cys, with consequent formation of a disulfide bridge between cys-25 and 
cys-82 (Srinivasan et al., 2006). The irreversible inactivation required oxygen, reduced 
GRx and oxidized GTX. Formation of the disulfide bond between cys-25 and cys-82 was 
dependent on the presence of oxygen (Fig. 2). 
Creatine kinase (CK) is also inhibited by GTX. Reaction with 100 μM GTX for 3 h 
resulted in a 50% loss of activity of CK (Hurne, Chai and Waring, 2000). Inactivation was 
reversed by addition of 10 μM DTT. CK contains four cysteinyl residues (73, 145, 253 and 
282). It was suggested that GTX caused the formation of an internal disulfide between 
Figure 2: Proposed model of sporidesmin as an inactivator of GRx. Reprinted with permission from 
Biochemistry, 45, Usha Srinivasan, Aveenash Bala, Shu-chuan Jao, David W. Starke, T. William 
Jordan, John J. Mieyal, Selective inactivation of glutaredoxin by sporidesmin and other 
epidithiopiperazinediones. 8978-8987, Copyright (2006) American Chemical Society. 
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Cys-73 and Cys-282 that are in close proximity. Two of four cys residues (253 and 282) also 
contained covalently bond GTX after treatment with 10 μM radiolabeled GTX (Fig. 3). CK 
may also be inactivated by ROS (Thomas, Carr and Winterbourn, 1994).  
Alcohol dehydrogenase (ADH) is also inhibited by GTX, with two suggested 
mechanisms: covalent modification or via free radical damage (Waring, Sjaarda and Lin, 
1995). In the first mechanism, GTX binds to either cys 281 or cys 282 that are located in 
the binding pocket for the nucleotide cofactor (Niederhut et al., 2001). The bound GTX 
might block this pocket preventing the necessary cofactor to bind. Addition of a 
reductant did not reverse the inhibition but increased it. The other mechanism relies on 
the ability of GTX to generate superoxide causing oxidative damage to ADH. The 
generation of ROS requires reduction of GTX which may explain why a reductant 
increased the inhibition of ADH (Fig. 4). 
 
 
 
1.4 Hypothetical interactions of GTX 
Based on the information presented above hypothetical pathways of GTX action 
can be proposed (Fig. 5). Oxidized GTX enters the cell and is subject to rapid reduction by 
GSH. The reduced GTX can either cycle back to its disulfide form and produce superoxide 
Figure 4: Proposed interaction of GTX with ADH. 
Reprinted from Biochemical Pharmacology, 49, Paul 
Waring, Allan Sjaarda, Qing H. Lin, Gliotoxin inactivates 
alcohol dehydrogenase by either covalent modification 
or free radical damage mediated by redox cycling, 1195-
1201, Copyright (1995), with permission from Elsevier. 
Figure 3: Theoretical interaction between GTX and CK. 
Reprinted with permission from Journal of Biological 
Chemistry, 275, Alanna M. Hurne, Christina L. L. Chai, Paul 
Waring, Inactivation of rabbit muscle creatine kinase by 
reversible formation of an internal disulfide bond induced by 
the fungal toxin gliotoxin, 25202-25206, Copyright (2000), 
American Society for Biochemistry and Molecular Biology. 
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or can interact with disulfide groups of proteins. Alternatively, oxidized GTX can also 
form disulfide bridges with protein cysteine thiols. Superoxide or other ROS could induce 
oxidative damage to DNA, lipids and proteins including oxidation of protein cysteines to 
sulfenic, sulfinic or sulfonic acids (SO1, SO2, SO3).  
 
 
 
1.5 Use of ICAT mass spectrometry to detect cysteine modification 
GTX apparently has a wide range of biological activities and can potentially modify 
protein cysteines that are involved in many different processes including protein 
structure and cellular regulation. Modification of such cysteines can lead to misfolded 
proteins, deregulation of cellular processes and inhibition of enzymes (for an overview 
see Pace and Weerapana, 2013). Possible targets of GTX could therefore be identified by 
Figure 5: Hypothetical reactions of GTX. 
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searching for modified cysteines. The isotope 
coded affinity tag (ICAT) process has potential 
to detect cysteine modification on a proteome-
wide scale. A modified ICAT process has been 
used to detect reactive cysteines of p21ras 
GTPase that are susceptible to modification by 
peroxynitrite and glutathione disulfide 
(Sethuraman et al., 2007), and redox sensitive 
thiols of protein disulfide isomerase (Kozarova 
et al., 2007). With the analysis of the membrane 
particulate fraction of the rabbit heart a more 
complex sample was analyzed using a modified 
ICAT approach (Sethuraman et al., 2004). 
ICAT was developed as a method to 
quantify proteins from two different samples. The ICAT method uses two labelling 
reagents: ‘ICAT light’ reagent with 12C and ‘ICAT heavy’ reagent with 13C. This isotope 
coding allows the differentiation of the two samples by mass spectrometry. ICAT 
reagents contain a biotin affinity tag, an acidic cleavable linker, a 12C or 13C isotope-coded 
tag, and a thiol-specific reactive group. The process begins with the incubation of the 
samples with the ICAT reagent. The reactive group of the ICAT reagent binds to 
accessible thiols of proteins (Fig. 6). 12C- and 13C-ICAT labelled samples are then combined 
and digested to obtain peptides. In further processing, the biotin affinity tag allows 
specific retrieval of ICAT-labeled peptides from the mixture. The linker is cleavable to 
reduce the size from 907 Da to 227 Da, or 916 Da to 236 Da, of the light ICAT label and the 
heavy ICAT label respectively (Fig. 7). In the following MS analysis the differentially 
labeled peptides are detected with a 9 Da mass differences. The relative intensities of 
these 9 Da mass pairs allows calculation of the ratio of light to heavy labeled peptides.  
The peptides can be further analyzed by tandem mass spectrometry (MS/MS) to 
acquire the peptide sequence and identify the protein. Collision-induced dissociation 
generates a fragment ion series which depends on the peptide sequence.  
Figure 6: Flowchart of the ICAT processing 
method. 
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ICAT requires free (reduced) cysteine thiols to label proteins. Modification of 
cysteines by GTX should therefore, in theory, be detectable using ICAT. Most simply, 
proteins that have cysteines modified by direct or oxidative interaction with GTX should 
show loss of ICAT labeling. In order to preserve the GTX-induced modifications the initial 
reducing step prior to labeling with ICAT needs to be excluded. 
  
Figure 7: ICAT reagent structure with the masses of the whole reagent, the cleavable part and the remaining isotope-
coded tag. 
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1.6 Aims of the study 
The goal of this study was to establish conditions for examination of protein 
modification using ICAT. Initially, cellular effects of GTX were examined using HL-60 cell 
cultures to define conditions where there might be protein change prior to substantial 
cytotoxicity including cell death. Assessment of cellular change was carried out using 
assays for cell viability, ROS production and cell cycling.  Attention was given to the 
number of cells in each assay as the effects of gliotoxin and other ETPs on cultured cells 
are dependent on the amount of toxin per cell as well as the concentration of toxin in the 
culture medium (Cordiner and Jordan, 1983; Jordan and Cordiner, 1987). 
ICAT labelling, without reduction of protein thiols, was then used to investigate the 
potential for detection of modified protein cysteines in extracts of the cultured cells. 
Workup of the ICAT-labelled proteins used a single one-step cleanup by ion exchange 
chromatography prior to capture of the biotin tagged proteins on an avidin column. 
Peptides were separated by reverse-phase liquid chromatography prior to MALDI MS and 
database searches were used to investigate whether modified cysteine containing 
peptides could be detected. 
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2 Methods 
GTX, molecular weight 326.39 from G. fimbriatum, was obtained from Sigma-Aldrich 
(Saint Louis, MO) with a purity of 98%. The GTX was dissolved in dimethyl sulfoxide 
(DMSO) to obtain a stock solution with a concentration of 5 mg/ml. Subsequent dilutions 
were made prior to the experiments. 
 
2.1 Cellular assays 
2.1.1 Cell culture 
HL-60 (human promyelocytic leukemia) cells were cultured in DMEM (Dulbecco’s 
Modified Eagle Medium, high glucose, HEPES, Gibco®, NY, USA) or RPMI 1640 medium 
(Roswell Park Memorial Institute, Gibco®) supplemented with 10% fetal calf serum (FCS) 
and 100 units/ml of penicillin and streptomycin. The cells were maintained in a humidified 
atmosphere with 5% CO2 at 37 °C. The cells were passage 1:10 or 1:5 when they reached 
approximately 80% visual confluency. 
 
2.1.2 Determination of cell number 
The cell number was determined using a haemocytometer and trypan blue (0.4% 
solution; Sigma-Aldrich). Samples (10 μl) of the HL-60 cell culture were combined 1:1 with 
the trypan blue solution. Ten microliters of this mixture was loaded on the 
haemocytometer and observed under a microscope. Cells which excluded the dye were 
considered as living cells and only those were considered for the cell number. 
 
2.1.3 Cell viability/metabolism assay 
The cytotoxic effects of gliotoxin on HL-60 cells were determined using an MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich) assay. In living,     
metabolically active cells, MTT is reduced to a purple formazan (Mosmann, 1983; 
Berridge, Herst and Tan, 2005).  
The cells were seeded into a 96-well plate at 2 x 104 cells in 100 μl per well. The cells 
were then treated with gliotoxin, DMSO (Sigma-Aldrich) or untreated for 24 h under cell 
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culture conditions. After the treatment, 20 μl of a MTT solution (5 mg/ml in PBS; 137 mM 
NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) was added to each well and 
incubated for 2 h under the same conditions. To dissolve the formazane crystals, 100 μl 
solubilizer (10% (w/v) SDS, 45% (v/v) dimethylformamide, pH 4.5) was added to each well 
and the plate was incubated overnight. The absorbance of each well was measured with 
a plate reader (2300 EnSpire® Multilabel Plate Reader, PerkinElmer, Waltham, MA) at 
585 nm. The results are expressed as the percentage metabolic activity of the DMSO-
treated control. 
 
2.1.4 Morphological assessment 
The morphology of cells was assessed using a Leica DMI 4000B microscope (Leica 
Camera AG, Solms, Germany) equipped with a CRAIC QDI 302 microscope 
spectrophotometer (CRAIC Technologies, San Dimas, CA) controlled by CCD Image 
Capture software (DFx41AF02, CRAIC Technologies) to acquire pictures of the cells. The 
cells were cultured in a 24-well plate at a density of 1 x 105 cells in 500 μl per well. The 
cells were treated for 24 h with various concentrations of GTX or with DMSO. 
 
2.1.5 Detection of reactive oxygen species 
2’,7’-Dichlorofluorescin diacetate (DCFDA, Sigma-Aldrich) was used to measure 
production of reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) in 
the cell upon gliotoxin treatment. DCFDA is cell permeable and can easily enter the cell. 
Once in the cell, it is deacetylated which makes it less cell permeable. In the presence of 
ROS/RNS DCDFA is oxidized to a fluorescent form. The fluorescence is correlated with 
the amount of ROS/RNS present (Wang and Joseph, 1999; Myhre et al., 2003). 
DCFDA was dissolved in DMSO resulting in a stock solution of 10 mM. HL-60 cells 
were harvested, washed with PBS and resuspended in 100 μl serum-free DMEM with 20 
μM DCFDA per 2 x 104 cells. The cells were incubated for 30 min at 37 °C. After the 
incubation, the cells were washed with PBS, resuspended in media with serum and 
seeded into a 96-well plate at 2 x 104 cells per well at a final volume of 100 μl. The 
fluorescence was measured with a plate reader (2300 EnSpire® Multilabel Plate Reader, 
PerkinElmer) in ‘well area scanning’ mode. This first measurement was taken as the 
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baseline. The cells were sedimented by centrifugation at 300 x g and the media was 
replaced with fresh media. GTX was added to the wells and the fluorescence was 
measured with a plate reader over 2 h at 10 min intervals. The negative controls were no 
treatment or DMSO only. Exposure to hydrogen peroxide was used as a positive control. 
 
2.1.6 Cell cycle analysis 
A flow cytometric method was used to determine the effects of gliotoxin on the 
cell cycle. The DNA was stained with DAPI (4',6-diamidino-2-phenylindole, Sigma-Aldrich). 
For each treatment, 2 x 106 cells were collected and incubated with DMSO, different 
concentrations of gliotoxin or no treatment for 24 h under cell culture conditions. The 
cells were then washed with PBS and resuspended in 0.5 ml PBS. The resuspended cells 
were transferred into 4.5 ml 70% ethanol while vortexing and stored at -20 °C until use, 
but at least overnight. After fixation, the cells were washed with PBS and stained with 1 
ml DAPI solution (1 μg/ml DAPI, 0.1% Triton X-100 in PBS) for 30 min. The stained cells 
were analysed using a BD LSR II flow cytometer (Becton Dickinson Biosciences, Franklin 
Lakes, NJ) with BD Cell Quest Pro software (v. 6.1.3). 
 
2.2 Mass spectrometry 
2.2.1 Cell treatment and preparation 
For the mass spectrometry analysis, 9 x 106 cells were cultured in 75 cm2 flasks in 
20 ml DMEM with GTX, DMSO as control, or untreated, for 3 h. Cells were then washed 
three times with nitrogen-flushed PBS. To the last wash, protease inhibitor (cOmplete 
mini protease inhibitor cocktail, Roche Diagnostics, Mannheim, Germany; 1 tablet per 10 
ml) was added. The cells were centrifuged at 300 x g in a tabletop centrifuge (MiniSpin®, 
Eppendorf AG, Hamburg, Germany) for 5 min and the supernatant was completely 
removed. The cell pellets were kept at -20 °C until used. 
 
2.2.2 Cell lysis and protein extraction 
The cell pellets were resuspended in 500 μl PBS with protease inhibitor and 
transferred to 2 ml tubes. The cells were homogenized using a Polytron® PT1200 
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(Kinematica AG, Lucerne, Switzerland) at full speed for 45 sec on ice and were 
centrifuged for 30 min at 16100 x g. Four volumes of Precipitation Agent (29 ml 
Precipitant 1, 1.7 ml Precipitant 2, 1.7 ml Precipitant 3, 1.7 ml Precipitant 4; ProteoExtract® 
Protein Precipitation Kit (Calbiochem, Merck KGaA, Darmstadt, Germany) was added to 
the supernatants and then incubated at -20 °C for 1 h. After centrifugation for 10 min at 
16100 x g, the pellets were washed two times by adding 500 μl cold Wash Solution 
(ProteoExtract® Protein Precipitation Kit, Calbiochem), vortexing and centrifuging for 
2 min at 14000 x g. Each pellet was dried at room temperature for 30 min with the tube 
left open and then stored at -20 °C until used. 
 
2.2.3 Protein quantification 
The protein pellets were resuspended in 40 μl Denaturing Buffer (Cleavable ICAT™ 
Kit; Applied Biosystems, Foster City, CA). Two microliters of the resuspended sample 
were processed along with BSA samples (2-D Quant Kit, GE Healthcare, Uppsala, 
Sweden) for a standard curve (10 μg, 20 μg, 30 μg and 40 μg BSA). To all samples, 500 μl 
Precipitant (2-D Quant Kit, GE Healthcare) was added and incubated for 3 min at room 
temperature. After the incubation 500 μl Co-Precipitant (2-D Quant Kit, GE Healthcare) 
was added to the samples and briefly vortexed. The samples were centrifuged for 5 min 
at 14000 x g. The supernatant was removed and 100 μl Copper Solution (2-D Quant Kit, 
GE Healthcare) and 400 μl High-Q water was added to the samples. The sample was 
vortexed to dissolve the pellet. To each sample 1 ml working color reagent (100:1 Color 
Reagent A with Color Reagent B; 2-D Quant Kit, GE Healthcare) was added and mixed by 
inversion. The sample was incubated for 20 min at room temperature. Aliquots (200 μl) 
from each sample and the standard curve were transferred to 96-well plate. The 
absorbance at 480 nm was measured in a plate reader using 200 μl High-Q water as the 
blank. 
 
2.2.4 ICAT labelling 
Initially, BSA was labelled with ICAT reagents (heavy and light; Cleavable ICAT™ Kit) 
at a 1:1 ratio as a proof of concept, and subsequently at a 1:4 ratio to evaluate the 
quantitation.  
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For the GTX experiments three sets of cell samples were analysed. In the first set 
proteins from cells treated with GTX were labelled with the ICAT reagent heavy and 
proteins from cells treated with DMSO were labelled with ICAT reagent light. The second 
set was a repetition of the first set with optimization of the LC and MS methods. In the 
third set proteins from untreated cells were labelled with ICAT reagent heavy and light 
regents as a control. In all cell samples the combination ratio of heavy and light reagents 
was 1:1. The cation exchange step was used for sample cleanup only and not for sample 
fractionation. Peptides eluted from a 0.2 ml cation exchange column were then subject 
to affinity purification on a 0.2 ml avidin cartridge to capture the biotin labelled cys-
containing peptides. Two fractions were collected from the avidin column – an eluate 
(flowthrough) of unlabelled peptides that should not contain reactive cys residues, and 
an eluate of the labelled cys-containing peptides. 
One hundred microgram of protein (BSA or extracted cell proteins) was dissolved 
in 80 μl denaturing buffer for each labelling. To each tube of BSA, 2 μl reducing reagent 
was added and the mixtures were heated at 100 °C for 10 min. The cell extracts, however, 
were not reduced. Each sample, BSA or cell extract, was added to one unit of cleavable 
ICAT reagent light (Cleavable ICAT™ Kit) and the other BSA or treated cell sample was 
added to one unit of cleavable ICAT reagent heavy (Cleavable ICAT™ Kit). The ICAT 
reagents were dissolved in 20 μl acetonitrile each before the samples were added. The 
mixtures were incubated for 2 h at 37 °C. The samples were combined by adding the 
content of the light reaction to the heavy reaction. The content of one vial trypsin from 
the ICAT Kit was dissolved in 200 μl distilled water and added to the combined samples. 
The digest was incubated for 16 h at 37 °C. The pH of the solution was adjusted to 2.5 to 
3.3 by adding Cation Exchange Buffer – Load and the samples were loaded on the cation 
exchange cartridge, washed with 1 ml Cation Exchange Buffer – Load and eluted by 
injecting 500 μl Cation Exchange Buffer – Elute. The labelled peptides were purified using 
an avidin cartridge, while the unlabelled peptides were washed of the cartridge (flow 
through). The eluted peptides from the cation cartridge were combined with Affinity 
Buffer – Load, dried in a centrifugal vacuum concentrator (Labconco Centrivap 
concentrator) and cleaved with 90 μl Cleaving Reagent A and B (95:5 ratio, Cleavable 
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ICAT™ Kit) for 2 h at 37 °C. The cleaved peptides were dried in a centrifugal vacuum 
concentrator. 
 
2.2.5 Peptide purification 
The ICAT labelled and cleaved samples were purified and concentrated using 
pipette tips with a C-18 matrix (PerfectPure C-18 tip, Eppendorf). Each sample was 
resuspended in 10 μl 0.1% trifluoroacetic acid (TFA). The pipette was set to 10 μl. A tip 
containing the C-18 matrix was pre-wetted by aspirating and discarding the Pre-Wet 
Solution (50% acetonitrile (ACN), 0.1% TFA) four times. Ten microliter aliquots of 
Equilibration/Wash Solution (0.1% TFA) were aspirated and discarded four times. The 
sample was loaded by aspirating and expelling ten times, and then washed by aspirating 
and discarding 10 μl Equilibration/Wash Solution five times. The sample was eluted into a 
fresh tube by aspirating and expelling 10 μl Elution Solution (80% ACN, 0.1% TFA) eight 
times. 
 
2.2.6 Direct spotting on a MALDI target 
Samples from the ICAT preparation, from either the cation exchange cleanup or 
from after the avidin purification were spotted directly on a MALDI target plate to 
monitor sample processing. 
Matrix solution was prepared by adding 10 mg α-cyano-4-hydroxycinnamic acid 
(CHCA; Sigma-Aldrich) to 1 ml 50% ACN with 0.1% TFA. The solution was vortexed for 45 
sec and centrifuged for 10 min at 14000 x g in a tabletop centrifuge. The supernatant 
(800 μl) was transferred into a fresh 1.5 ml tube. The sample (1 μl) was combined with 
matrix at a ratio of 1:1 and 1:10. From the sample-matrix mixture, 1.5 μl was spotted on a 
MALDI target plate and dried overnight at room temperature. For internal calibration, 
the calibration mixture (ProteoMass™ Peptide & Protein MALDI-MS Calibration Kit, 
Sigma) was resuspended in matrix and 1.5 μl aliquots were spotted on the plate. 
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2.2.7 Liquid chromatography 
A Tempo LC MALDI Plate spotting system with a Chromolith RP-18e column was 
used for chromatography of the ICAT labelled peptides and to combine them with matrix 
(50% ACN, 0.1% TFA; containing 10 mg/ml CHCA) and spot on a MALDI plate. 
The purified samples were dissolved in 20 μl LC Reagent A (2% ACN, 0.1% TFA) and 
7 μl were injected into the chromatograph. The LC program started at 98% Reagent A and 
2% Reagent B (98% ACN, 0.1% TFA). Over 40 min the percentage of Reagent B was 
increased to 80% while decreasing Reagent A. The flow table is shown in Appendix A. The 
eluted sample was combined with matrix (1:1 ratio for BSA and first cell sample, 1:5 ratio 
for second and third cell samples) and every 16 sec the fraction was spotted on a MALDI 
target plate. After liquid chromatography a calibration mixture was spotted on the plate 
(see ‘Direct spotting on a MALDI target’) and the spots were dried on the plate overnight 
at room temperature. 
 
2.2.8 Tandem mass spectrometry 
The peptides were analysed using an AB SCIEX TOF/TOF™ 5800 mass spectrometer 
(Applied Biosystems) controlled by TOF/TOF™ Series Explorer™ software V.4.1.0. The MS 
and MS/MS spectra were acquired using continuous stage motion and a laser intensity 
between 4600 and 5200 for MS spectra and 5200 for MS/MS spectra. Per spectrum, 400 
shots were fired and the spectra accumulated to the final spectrum. 
Prior to sample analysis each plate was calibrated using a calibration standard. The 
fragment ions of adrenocorticotropic hormone fragment 18-39 (2465.1989 Da) were used 
for MS/MS calibration. A list of peptides used for MS and MS/MS calibration can be found 
in Appendix X. 
 
2.2.9 One-dimensional gel electrophoresis 
Protein recovery and digestion during ICAT processing was monitored by one-
dimensional gel electrophoresis. The samples (1 μl) were combined with 2.5 μl LDS 
sample buffer (4x, NuPAGE®; Invitrogen, Carlsbad, CA), 1 μl reducing agent (10x, 
NuPAGE®, Invitrogen) and 5.5 μl High-Q water. The prepared samples were loaded on 
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4-12% Bis-Tris gels and electrophoresed at 200 V, 100 mA for 55 min in MOPS SDS running 
buffer (Invitrogen). To the buffer in the inner chamber 500 μl antioxidant (Invitrogen) 
was added before the start of the electrophoresis. 
Electrophoresed gels were stained with Coomassie Briliant Blue G-250 (Bio-Rad, 
Hercules, CA). The gels were fixed in fixing solution (50% ethanol, 3% phosphoric acid) for 
30 min with continuous shaking and washed in High-Q water three times for 30 min. 
Fixed gels were incubated for three days in staining solution containing 34% methanol, 
17% ammonium sulphate, 3% phosphoric acid and 10 mg Coomassie powder. The stained 
gels were washed with High-Q water three times for 30 min. 
Images of the stained gels were acquired using an Image Scanner III (GE 
Healthcare, Uppsala, Sweden) controlled by LabScan 6.01 software (GE Healthcare) using 
transparency mode and a resolution of 200 dpi. 
 
2.2.10 Data analysis 
The acquired data were analysed with Mascot Distiller v. 2.4.3.3 (Matrix Science, 
UK) with the Quantitation Toolbox. Briefly, the raw data from the mass spectrometer 
were imported into Distiller. For each peak in the MS and MS/MS spectra the correlation 
between the predicted and the observed isotope distribution was calculated. Peaks with 
a correlation below 0.6 or a signal-to-noise ratio below 4 were rejected. The peak lists 
were than uploaded to Mascot (Perkins et al., 1999) to perform the searches. The results 
from the Mascot search were combined with the raw data and the identified peptides 
grouped together. From the raw data the intensity (peak area) of the identified ICAT 
pairs was calculated. Only peptides with a Mascot score indicating at least homology 
were included in the quantitation. In the case of a missing ICAT partner Distiller searched 
for parent ions matching the expected mass and which eluted in the same time frame. 
Another correlation coefficient between the predicted and the observed isotope 
distribution was used to detect interfering peaks. A correlation coefficient below 0.7 led 
to an exclusion of the quantitation. Precursors detected in multiple fractions were 
accumulated to one ratio and the standard error was calculated. For proteins with more 
than one peptide identified the geometrical standard deviation was calculated. 
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The precursor masses and fragment ion peaks were searched against Uniprot, 
human, 30/10/2013, 850,499 sequences using the Mascot algorithm (Mascot Server v. 
2.4.1, Matrix Science, London, UK). The search settings were 0.8 Da for both peptide and 
MS/MS tolerance, trypsin digestion with one missed cleavage, and ICAT ABI Cleavable as 
quantitation method. 
Successfully identified peptides were quantified using the Quantitation Toolbox. 
Only peptides with a standard error below 0.1 and a correlation value above 0.7 were 
included in the quantitation. The quantitation were given as a ratio of peptides labelled 
with ICAT reagent light (L) to peptides labelled with ICAT reagent heavy (H). The 
quantitation method was updated according to the Certificate of Analysis of the ICAT Kit 
to correct for impurities of 13C in the heavy ICAT reagent. 
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3 Results 
3.1 Cellular effects of GTX 
The cellular effects of GTX were initially examined using MTT. Preliminary 
experiments investigated the effects of culture medium, cell number, amount of GTX, 
and incubation time to establish the assay conditions (data not shown). The linearity of 
the assay was also 
investigated to confirm that 
measured changes in 
absorbance were 
proportional to metabolic 
reduction of MTT. This was 
done using a range of cell 
numbers without exposure 
to GTX (Fig. 8). The response 
was linear over the 
measured range and 
reduction was greater in 
DMEM than in RPMI. In 
general the expected 
response of cytotoxic compounds in the MTT assay is to decrease metabolic reduction of 
MTT which is interpreted as a decrease in cell viability, but more precisely diminished 
metabolism. The preliminary experiments, however, had indicated that GTX enhanced 
the reduction of MTT by HL60 cells under some conditions, especially at high 
concentrations of GTX.  Possible explanations included direct reduction of MTT by GTX 
dithiol produced from GTX disulfide by reaction with GSH or other cellular reducing 
systems. 
For subsequent MTT experiments standard conditions were fixed at 
2x 104 cells/well (100 μl incubates) in 96-well plates and the effects of GTX concentration 
and incubation time were investigated.  
HL-60 cells treated with GTX for 24 h showed decreased viability starting at 10 ng/ml 
(Fig. 9). Cells cultured in RPMI seemed to be slightly less susceptible compared to cells in 
Figure 8: Effects of cell number on relative absorption of MTT assay in 
different culture media. Representative results from three experiments. 
Cells were cultured in DMEM (filled circle) or RPMI (empty cicle). The 
experiemtens were conducted in 96-well plates. The error bars represent 
the standard deviation for three replicates. 
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DMEM. The IC50 values were approximately 77 and 86 nM for DMEM and RPMI 
respectively. 
Effects on the metabolism of MTT were less in cell exposed to GTX for 1 or 3 h (Fig. 
10). Only small decreases in metabolism of MTT occurred when in cells in DMEM were 
exposed to GTX for 1 h although cells in RMPI seemed to be more sensitive to (Fig 10A). 
At 3 h, however, there were greater losses in viability (Fig. 10B):  GTX at 1 μg/ml again had 
less effect in DMEM, approximately 30% decrease in viability, compared to RPMI. 
Unexpectedly, reduction of MTT was less affected  at 10 μg/ml GTX but this was not 
investigated further.  
Culture in DMEM was used for all subsequent experiments, but cell numbers and 
Figure 10: MTT results from HL-60 cells cultured in DMEM (filled circle) and RPMI (empty circle) and treatment with 
various GTX concentrations for 1 h (A) and 3 h (B). Representative results from five experiments in 96-well plates. The 
error bars represent the standard deviation of 3 replicates. The error bars represent the standard deviation of three 
replicates. 
A B 
Figure 9: Concentration-dependent 
effects of GTX on HL-60 cell 
metabolism. Representative results 
from seven experiments conducted 
in 96-well plates. Cells were cultured 
in DMEM (filled circle, continuous 
line) or RPMI (empty circle, dashed 
line) in the presence of GTX. The 
error bars represent the standard 
deviation for three replicates. 
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culture volumes had to be adjusted depending on the numbers of cells required for 
different assays.    
 
3.1.1 Measurement of ROS production 
Some of the effects of GTX might be attributed to its capability to produce ROS. 
Dichlorofluorescein diacetate was therefore used as a probe to measure the production 
of ROS during GTX exposure. These experiments were carried out in 96-well plates using 
conditions similar to the MTT assays, namely 2x 104 cells in 100 μl DMEM per well. As a 
positive control, cells were exposed to 100 µM hydrogen peroxide which resulted in an 
increase in fluorescence with greatest change in the first 45 min (Fig. 11). Untreated 
control cells, and cells cultured with 1 μg/ml and 10 μg/ml GTX, showed a much smaller 
increase in fluorescence signal over time.  
 
3.1.2 Effects of GTX on cell morphology 
For analysis of morphological change cultures in 24-well plates containing 105 cells 
in 500 μl DMEM were exposed to up to 5 μg/ml GTX for 24 h. Little obvious change was 
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Figure 11: Changes in fluorescence of DCF-DA loaded cells after treatment with DMSO (red line), GTX (green and 
purple line), hydrogen peroxide (cyan line) and no treatment (blue line) over time. Cells were cultured in DMEM 
and loaded with DCF-DA. The fluorescence was measured dircetly after addition of the treatments. Shown are the 
representative results of five experiments conducted in 96-well plates with 2 x 104 cells per well. The error bars 
represent the standard deviation of three replicates. 
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observed using phase contrast microscopy (Fig. 12) but the number of dead cells  
detected by trypan blue staining increased in the GTX –containing cultures. 
 
3.1.3 Cell cycle analysis 
Cell cycle analysis using DAPI staining was carried out using cells cultured in DMEM 
with GTX for 24 h. Control cells, and cells cultured with DMSO, showed G1 and G2 peaks 
with an apparent smaller population of apoptotic cells (Fig. 13). In three separate 
experiments, cells exposed to 0.1 μg/ml GTX showed little change from controls but 
culture for 24 h with 1 μg/ml GTX (Fig. 13 D) resulted in increased cell death and a G1 block 
of the cell cycle with the substantial loss of cells in G2/M. 
  
Figure 12: HL60 after 24h of treatment with different GTX concentrations, DMSO or no treatment. No obvious 
morphological changes were visible in the GTX-treated cells compared to control. Cells treated with GTX 
concentrations above 0.01 μg/ml showed a reduction in cell density. The cells were cultured in 24-well plates. 
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3.2 ICAT Analysis of Protein Modification 
3.2.1 ICAT labelling of BSA 
 
Initially, the workflow was examined using a 1:1 mixture of light and heavy ICAT-
labelled BSA. Labelled peptides were examined using ion exchange cleanup prior to 
offline LC-MALDI in which peptides separated by LC on the TEMPO were mixed with 
CHCA matrix prior to MALDI MS and MS/MS.  BSA was identified with a Mascot score of 
18405 from a total of 661 MS ions representing 25 ICAT labelled peptide sequences. The 
protein sequence coverage was 41% (Fig. 14). The ratio between light and heavy labelled 
protein determined by Distiller was 0.94 with a geometrical standard deviation of 1.2. The 
resulting confidence interval was 0.78 to 1.14.The protein false discovery rate (homology) 
was 1.4%. Peptides with a standard error above 0.1 and a correlation below 0.7 were 
excluded from the quantitation leaving 21 of 25 peptides for the quantitation. The 
Figure 13: Cell cycle analysis of HL-60 cells treated with DMSO (B), GTX 
(C and D) and no treatment (A). Cells were cultured in DMEM in 
presence of the treatment for 24 h and stained with DAPI. A, 
apoptotic cells; G0/G1, G0/G1-phase; S, S-phase; G2/M, G2-/mitotic phase. 
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theoretical list of cysteine-containing tryptic peptides is shown in Table 1 and identified 
peptides with the corresponding ratios are in Table 1. 
A representative peptide pair (CCTESLVNR, ratio L/H 0.9995) is shown in Figure 15A. 
The corresponding MS/MS spectra from the peptide with the light ICAT tag showed a y 
ion fragment (RNVLSETC) at 1148.61 Da (Fig. 15B). The same fragment of the heavy 
tagged peptide was at 1157.63 Da (Fig. 15C); illustrating the successful ICAT labelling and 
the resulting mass difference of 9 Da per labelled cys. 
In a second experiment using BSA with a 1 to 4 (light:heavy) labelling ratio, the 
Mascot score was 7473 from 20 identified peptides (294 ICAT ions).  The experimentally 
determined light:heavy (protein) ratio was 0.23 using 18 of the identified peptides  with a 
geometrical standard deviation of 1.39,  and a confidence interval of 0.16 to 0.32. The 
reported protein FDR (homology) was 0.4% and the protein coverage was 45% (Fig. 14). 
The identified peptides with their L/H ratios are listed in Table 1. 
Not all of the potential cys-containg peptides were detected using the 1:1 labelling 
ratio, and less were detected with 1:4 labelling. In general, tryptic peptides terminated by 
arginine are more readily detected than those with lysine when using MALDI and the 
optimum mass range for peptide detection using CHCA matrix is 800-3000 m/z.  
 
  
Figure 14: Comparison of protein coverage of the two BSA samples. Red indicates identified peptides and blue 
theoretical not identified cys-containing peptides. 
 
  BSA sample ratio 1 to 1  BSA sample ratio 1 to 4 
1  MKWVTFISLL LLFSSAYSRG VFRRDTHKSE IAHRFKDLGE  MKWVTFISLL LLFSSAYSRG VFRRDTHKSE IAHRFKDLGE 
41  EHFKGLVLIA FSQYLQQCPF DEHVKLVNEL TEFAKTCVAD  EHFKGLVLIA FSQYLQQCPF DEHVKLVNEL TEFAKTCVAD 
81  ESHAGCEKSL HTLFGDELCK VASLRETYGD MADCCEKQEP  ESHAGCEKSL HTLFGDELCK VASLRETYGD MADCCEKQEP 
121  ERNECFLSHK DDSPDLPKLK PDPNTLCDEF KADEKKFWGK  ERNECFLSHK DDSPDLPKLK PDPNTLCDEF KADEKKFWGK 
161  YLYEIARRHP YFYAPELLYY ANKYNGVFQE CCQAEDKGAC  YLYEIARRHP YFYAPELLYY ANKYNGVFQE CCQAEDKGAC 
201  LLPKIETMRE KVLASSARQR LRCASIQKFG ERALKAWSVA  LLPKIETMRE KVLASSARQR LRCASIQKFG ERALKAWSVA 
241  RLSQKFPKAE FVEVTKLVTD LTKVHKECCH GDLLECADDR  RLSQKFPKAE FVEVTKLVTD LTKVHKECCH GDLLECADDR 
281  ADLAKYICDN QDTISSKLKE CCDKPLLEKS HCIAEVEKDA  ADLAKYICDN QDTISSKLKE CCDKPLLEKS HCIAEVEKDA 
321  IPENLPPLTA DFAEDKDVCK NYQEAKDAFL GSFLYEYSRR  IPENLPPLTA DFAEDKDVCK NYQEAKDAFL GSFLYEYSRR 
361  HPEYAVSVLL RLAKEYEATL EECCAKDDPH ACYSTVFDKL  HPEYAVSVLL RLAKEYEATL EECCAKDDPH ACYSTVFDKL 
401  KHLVDEPQNL IKQNCDQFEK LGEYGFQNAL IVRYTRKVPQ  KHLVDEPQNL IKQNCDQFEK LGEYGFQNAL IVRYTRKVPQ 
441  VSTPTLVEVS RSLGKVGTRC CTKPESERMP CTEDYLSLIL  VSTPTLVEVS RSLGKVGTRC CTKPESERMP CTEDYLSLIL 
481  NRLCVLHEKT PVSEKVTKCC TESLVNRRPC FSALTPDETY  NRLCVLHEKT PVSEKVTKCC TESLVNRRPC FSALTPDETY 
521  VPKAFDEKLF TFHADICTLP DTEKQIKKQT ALVELLKHKP  VPKAFDEKLF TFHADICTLP DTEKQIKKQT ALVELLKHKP 
561  KATEEQLKTV MENFVAFVDK CCAADDKEAC FAVEGPKLVV  KATEEQLKTV MENFVAFVDK CCAADDKEAC FAVEGPKLVV 
601  STQTALA     STQTALA    
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Table 1: Theoretical cys-containing tryptic peptides of BSA. MC,  missed cleavages; I, identified but excluded from 
quantitation. Oxidation of methionine was used as variable modification during database searches. 
Peptide 
mass 
MC Peptide sequence # of 
cys 
L/H ratios 
BSA 
1:1 
BSA 
1:4 
3579.856 1 GLVLIAFSQYLQQCPFDEHV KLVNELTEFAK 1   
3503.571 1 HPYFYAPELLYYANKYNGVF QECCQAEDK 2   
3390.683 1 DLGEEHFKGLVLIAFSQYLQ QCPFDEHVK 1   
2952.429 1 SHCIAEVEKDAIPENLPPLT ADFAEDK 1   
2867.184 1 EYEATLEECCAKDDPHACYS TVFDK 3   
2829.337 1 CCTESLVNRRPCFSALTPDE TYVPK 3   
2701.245 1 CCTKPESERMPCTEDYLSLI LNR 3   
2693.200 1 TCVADESHAGCEKSLHTLFG DELCK 3   
2494.159 1 LVNELTEFAKTCVADESHAG CEK 2   
2490.255 1 MPCTEDYLSLILNRLCVLHE K 2   
2472.198 1 QNCDQFEKLGEYGFQNALIV R 1   
2441.169 1 AFDEKLFTFHADICTLPDTE K 1   
2435.243 0 GLVLIAFSQYLQQCPFDEHV K 1   
2414.170 1 RPCFSALTPDETYVPKAFDEK 1   
2401.159 1 DAIPENLPPLTADFAEDKDVCK 1 I 0.21 
2387.144 1 DDSPDLPKLKPDPNTLCDEF K 1   
2316.046 1 YNGVFQECCQAEDKGACLLPK 3   
2298.118 1 HLVDEPQNLIKQNCDQFEK 1   
2220.137 1 LFTFHADICTLPDTEKQIK 1   
2174.029 1 ECCDKPLLEKSHCIAEVEK 3   
2105.934 1 TVMENFVAFVDKCCAADDK 2 0.68  
2121.929 1 TVMENFVAFVDKCCAADDK + Oxidation 2 0.80 0.21 
2076.878 1 ECCHGDLLECADDRADLAK 3 1.46  
2034.058 1 EACFAVEGPKLVVSTQTALA  1   
2003.778 1 ETYGDMADCCEKQEPER 2 0.77  
2019.773 1 ETYGDMADCCEKQEPER + Oxidation 2 I  
1962.948 1 LKPDPNTLCDEFKADEK 1   
1942.820 1 VHKECCHGDLLECADDR 3 0.84  
1890.803 1 VASLRETYGDMADCCEK 2   
1888.995 1 SLHTLFGDELCKVASLR 1   
1884.901 1 ADLAKYICDNQDTISSK 1   
1850.899 0 LFTFHADICTLPDTEK 1 0.97 0.21 
1844.848 1 NECFLSHKDDSPDLPK 1   
1823.900 0 RPCFSALTPDETYVPK 1 1.00 0.30 
1756.734 1 CCAADDKEACFAVEGPK 3 0.79 0.14 
1738.811 1 DDPHACYSTVFDKLK 1 0.78 0.16 
1700.787 1 LAKEYEATLEECCAK 2   
1667.813 0 MPCTEDYLSLILNR 1 0.92 0.29 
1683.808 0 MPCTEDYLSLILNR + Oxidation 1 0.97 0.21 
1633.662 0 YNGVFQECCQAEDK 2   
1627.800 1 YICDNQDTISSKLK 1   
1616.749 1 QEPERNECFLSHK 1  0.43 
1578.598 0 ECCHGDLLECADDR 3 0.86 0.19 
1519.746 0 LKPDPNTLCDEFK 1  0.20 
1497.631 0 DDPHACYSTVFDK 1   
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Peptide 
mass 
MC Peptide sequence # of 
cys 
L/H ratios 
BSA 
1:1 
BSA 
1:4 
1482.798 1 LCVLHEKTPVSEK 1   
1465.689 1 VGTRCCTKPESER 2   
1418.738 1 LKECCDKPLLEK 2   
1388.571 0 EYEATLEECCAK 2 1.00 0.30 
1386.621 0 YICDNQDTISSK 1 0.96 I 
1364.480 0 ETYGDMADCCEK 2   
1380.475 0 ETYGDMADCCEK + Oxidation 2 1.49  
1362.672 0 SLHTLFGDELCK 1 0.96 0.22 
1352.666 1 VTKCCTESLVNR 2   
1349.546 0 TCVADESHAGCEK 2 0.91 0.23 
1331.717 1 GACLLPKIETMR 1   
1197.557 1 DVCKNYQEAK 1   
1177.559 0 ECCDKPLLEK 2 1.01 I 
1138.567 1 CASIQKFGER 1   
1052.450 0 CCTKPESER 2 0.99 0.39 
1050.492 0 EACFAVEGPK 1 0.98 0.26 
1024.455 0 CCTESLVNR 2 1.00 0.39 
1015.488 0 SHCIAEVEK 1 I 0.13 
1011.420 0 QNCDQFEK 1   
977.4509 0 NECFLSHK 1   
918.5189 1 LRCASIQK 1   
841.460 0 LCVLHEK 1   
725.2593 0 CCAADDK 2 I  
701.4014 0 GACLLPK 1   
649.3338 0 CASIQK 1   
464.2173 0 DVCK 1   
 37 
 
  
Figure 15: MS of an ICAT pair 
of the peptide CCTESLVNR (A). 
The red line represents the 
accquired spectra and the 
black line shows the area used 
for the quantitation. The 
section of the MS/MS of the 
light ICAT labelled petide 
shows the y-ion fragment 8 at 
m/z 1148.6 (B). The same y-ion 
from the heavy labelled 
peptide was at 1157.6 (C). The 
blue lines represent the y-ion 
series and the green on the b-
ion series. The same peptide 
of the 1 to 4 sample showed an 
increased intensity of the 
heavy labelled peptide (D). 
A 
B 
C 
D 
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3.2.2 ICAT analysis of the effects of GTX on HL60 cells 
ICAT was originally developed as a method for comparison of variation in protein 
abundance based on labelling free cysteinyl residues. In this approach biological extracts 
are reduced to convert oxidized protein cysteines, including disulfides, to the free thiols 
prior to labelling with ICAT reagents (Gygi et al., 1999; Hansen et al., 2003). Alternatively, 
as investigated here, the reduction step can be omitted to probe differences in cysteine 
reactivity between experimental groups. The hypotheses for my experiments are that: 
GTX modifies cysteinyl residues by either (1) reaction of GTX disulfide with protein thiols 
to form mixed disulfide adducts, or (2) by oxidation of cysteine through the production 
of ROS, or (3) possibly by interaction of GTX dithiol with protein disulfides; and that such 
changes may be detected by non-reductive labelling with ICAT reagents. 
In total, three ICAT experiments were carried out (Table 2). In all experiments 9 x 
106 cells cultured for 3 h in DMEM were used. In the first two experiments proteins from 
cells that had been exposed to 1 μg/ml GTX (added in DMSO) were heavy-labelled and 
compared to light-labelled proteins from control cells that had been incubated with 
1μl/ml DMSO. Experiments Two (2a) and Three (2b) were carried out together with 
comparison of light and heavy labelled control cells in the third experiment (Table 2).  
One-dimensional SDS-PAGE was used to confirm tryptic digestion during sample 
processing. The MALDI MS of total peptide extracts was used to confirm the presence of 
peptides before and after the chromatographic steps, and off-line (TEMPO) MALDI was 
used for peptide identification and analysis of ICAT labelling. 
 
Table 2: Overview of the ICAT experiments with the respective treatment and labelling strategy. 
# Sample Treatment (3h) Label 
1 HL-60 DMSO (1 µl/ml) ICAT light 
HL-60 GTX (1 µg/ml) ICAT heavy 
2a HL-60 DMSO (1 µl/ml) ICAT light 
HL-60 GTX (1 µg/ml) ICAT heavy 
2b HL-60 - ICAT light 
HL-60 - ICAT heavy 
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3.2.2.1 ICAT Experiment One: Comparison of GTX-exposed with control cell extracts 
HL-60 cells were exposed to GTX or DMSO (control) as indicated in Table 2 and 
labelled with ICAT reagents. Sample processing was monitored by SDS PAGE (Fig 16). 
There were some differences (arrows) in the protein profiles of GTX and DMSO exposed 
cells before labelling. Protein bands at 100 kDa, 16 kDa and 12 kDa were more intense in 
the GTX treated sample, while a band at >250 kDa was more intense in the DMSO-treated 
sample (Fig. 16A). Although the ICAT-labelled samples were more dilute there was 
staining of sample proteins but the bands were too faint to confirm any differences (Fig. 
16B). Lane GD (Fig. 16C) represents the tryptic digest of combined light and heavy-
labelled samples prior to chromatography and cleavage of the biotin tag.  As expected, 
protein was not detected in the tryptic digest although sample dilution was not greater 
than in the ICAT-labelled lanes. Accumulation of Coomassie staining was visible at the 
electrophoresis front suggesting the presence of peptides resulting from the tryptic 
D G 
250 
150 
100 
75 
50 
37 
25 
20 
15 
10 
A 
D G GD 
B 
Figure 16: 1D gel of cells treated with DMSO (D) and GTX (G) before 
(A) and after ICAT labelling (B), and after trypsin digest (C). Arrows 
indicate the changes in the GTX-treated sample. 
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C 
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digestion. 
Prior to RP-LC fractionation the presence of peptides and ICAT pairs was verified by 
MALDI MS. Post-avidin-cleanup samples were combined with matrix and spotted on a 
MALDI target plate. MS analysis showed ten putative ICAT pairs (Fig. 17). These ICAT pairs 
confirmed the successful labelling with the ICAT reagents. 
The labelled peptides were fractionated by RP–LC and spotted onto a MALDI plate 
using the TEMPO LC-spotter. The UV-trace showed elution of peptides in fractions 50 to 
95 (Fig. 18). MALDI MS and MS/MS of 210 LC fractions resulted in matching of 35 MS ions 
to nine putative ICAT-labelled cys-containing peptides from eight proteins (Table 3). Two 
different peptide sequences matched to peptidyl-prolyl cis-trans isomerase. Of these nine 
peptides, six showed light to heavy ICAT ratios ranging from 0.22 to 4.02 with only one 
apparent pair having a ratio near unity (isoform 4 of Protein sidekick-2). Proteins that 
showed apparent loss following exposure to GTX (light/heavy >1) included tubulin beta-
4A chain, glyceraldehyde-3-phosphate dehydrogenase and peptidyl-prolyl cis-trans 
isomerase. Two proteins (albumin, hnRNP A1) had ratios <1 indicating increase following 
exposure to GTX.  
Figure 17: MS of ICAT labelled peptides from Experiment One prior to RP-LC fractionation. 
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For pyruvate kinase and cDNA FLJ56548 quantitation was not possible as the 
standard error of the accumulated ratios was higher than 0.1, therefor the peptides were 
rejected from the quantitation. The standard error represents the variation within these 
precursors. 
 
Table 3: List of identified proteins, accession numbers and ratios from Experiment One. 
 Protein description Uniprot 
accession 
# 
Score1 Ratio 
Light/ 
Heavy 
Sequence 
1 Tubulin beta-4A chain M0QX14 169 4.02282 3EIVHLQAGQCGNQIGAK19 
2 Glyceraldehyde-3-
phosphate 
dehydrogenase 
Q0QET7 164 1.89752 210VPTANVSVVDLTCR223 
3 Peptidyl-prolyl cis-trans 
isomerase 
B4DM82 145 2.37153 56IIPGFMCQGGDFTR69 
4 Serum albumin H0YA55 111 0.21742 345CCTESLVNR353 
5 Heterogeneous nuclear 
ribonucleoprotein A1 
(Fragment) 
H0YH80 39 0.45952 38YHTVNGHNCEVR49 
6 cDNA FLJ56548, highly 
similar to Elongation 
factor 2 
B4DPU3 37 No 
quantific
ation4 
436CLYASVLTAQPR447 
7 Pyruvate kinase H3BQ34 31 No 
quantific
ation4 
44NTGIICTIGPASR56 
8 Isoform 4 of Protein 
sidekick-2 
Q58EX2-4 25 1.12802 2169MCVASSSSALR2179 
1: Protein score calculated by Mascot 
2: based on one identified peptide 
3: based on two different peptides 
4: rejected because the standard error was above the threshold of 0.1 
Figure 18: UV trace of the RP separation of ICAT labelled peptides from Experiment One using the TEMPO LC-spotter.  
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3.2.2.2 ICAT Experiment Two (2a): Comparison of GTX-exposed with control cell extracts 
HL-60 cells were prepared as indicated in Table 1. Again, the sample processing was 
monitored by SDS PAGE (Fig 19). There were the same differences (arrows) in the protein 
profiles of GTX and DMSO exposed cells before labelling as in Experiment One, except 
for the protein band at 100 kDa that in this experiment did not differ between  the GTX- 
and the DMSO-treated samples (Fig. 19A). As in Experiment One, the higher dilution of 
the ICAT-labelled samples prevented a precise analysis of the protein bands but 
nevertheless confirmed the presence of proteins after the labelling (Fig. 19B). The tryptic 
digest of combined light and heavy-labelled samples prior to further processing showed 
no visible protein bands for GTX- and DMSO-treated samples (Fig. 19C, lane GD) or for the 
control samples (Fig. 12C, lane C1C2).  
The presence of peptides and ICAT pairs was verified by MALDI MS of the samples 
eluted from the avidin column. A total of eight putative pairs could be identified (Fig. 20). 
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electrophoresis 
of GTX-treated 
(G), DMSO-
treated (D) and 
untreated (C1 & 
C2) samples 
prior to labelling 
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labelling (B) and 
post trypsin 
digest (C). 
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Three pairs were similar to the ones from Experiment One: 1195/1204, 1210/1219 and 
1712/1721. 
 
The LC method was modified to achieve a better resolution. The proportion of LC 
reagent B was changed from 20% to 50% over 30 min followed by steep increase to 80% 
Figure 21: UV trace of the RP separation of ICAT labelled peptides from Experiment 2a using the TEMPO LC-spotter.  
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Figure 20: MS spectra of ICAT labelled peptides from Experiment 2a prior to RP-LC fractionationing. 
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instead of a gradual change from 0% to 80%. The changes generated a wider peptide 
elution range from fractions 40 to 100 (Fig. 21). 
MS and MS/MS of the 224 LC fractions led to identification of 56 MS ions matching 
to 11 putative ICAT-labelled peptides from ten proteins (Table 4). Titin was identified with 
two matching peptides. Only two proteins, myotonin protein kinase and von Willebrand 
factor A domain-containing protein 3A, were quantified. Myotonin-protein kinase 
showed a ratio near unity, while the ratio of von Willebrand factor A domain-containing 
protein 3A was 40.6, indicating a strong increase following GTX treatment. The peptides 
of the other identified proteins, phosphoglycerate kinase, acidic leucine-rich nuclear 
phosphoprotein, titin, vacuolar protein sorting-associated protein 13B, pleckstrin 
homology domain-containing family M member 2, uncharacterized protein (J3QRJ0), 
anaphase-promoting complex subunit 4 and peptidyl-prolyl cis-trans isomerase G, had 
standards errors > 0.1 leading to exclusion from the quantitation. 
 
Table 4: List of identified proteins, accession numbers and determined ratios from Experiment 2a. 
 Protein description Uniprot 
accession # 
Score1 Ratio Light/ 
Heavy 
Sequence 
1 Phosphoglycerate 
kinase 
B7Z7A9 59 No 
quantificati
on3 
ACANPAAGSVILLENLR 
2 Acidic leucine-rich 
nuclear 
phosphoprotein 32 
family member A 
H0YN26 32 No 
quantificati
on3 
SLDLFNCEVTNLNDYR 
3 Titin Q8WZ42-5 19 No 
quantificati
on3 
NVDSVVNGTCR, 
VLDSPGPCGK 
4 Vacuolar protein 
sorting-associated 
protein 13B 
Q7Z7G8 19 No 
quantificati
on3 
AMLNISESCR 
5 Pleckstrin homology 
domain-containing 
family M member 2 
Q5VVD7 19 No 
quantificati
on3 
TCFVVLSNGILYQYPDR 
6 Myotonin-protein 
kinase 
M0R333 17 0.902 GEVSCFR 
7 Uncharacterized 
protein 
J3QRJ0 16 No 
quantificati
on3 
CSGGAGAVLR 
8 Anaphase-promoting 
complex subunit 4 
E9PCR4 15 No 
quantificati
on3 
SMNQAICIPLYR 
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 Protein description Uniprot 
accession # 
Score1 Ratio Light/ 
Heavy 
Sequence 
9 Peptidyl-prolyl cis-trans 
isomerase G 
C9JM79 15 No 
quantificati
on3 
MPGLSCGGGR 
10 von Willebrand factor A 
domain-containing 
protein 3A 
A6NCI4 14 40.62 VCILLDTSGSMGPYLQQVK 
1 Protein score calculated by Mascot 
2 based on one identified peptide 
3 rejected because the standard error was above the threshold of 0.1 
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3.2.2.3 ICAT Experiment Two (2b): Comparison of heavy- and light-labelled control cells 
HL-60 cells were processed in the same manner as for experiment 2a. Both samples 
contained untreated cells only as indicated in Table 2. The LC method was retained as 
Experiment No. 2. The UV trace showed a similar peptide elution profile as in Experiment 
No. 2A with a higher peak intensity (Fig. 22). Overall, 224 LC fractions were collected. 
MADLI MS of the sample eluted from the avidin column was used to identify 
putative peptides and ICAT pairs. In total, ten putative ICAT pairs were identified (Fig. 23). 
Seven of the ten pairs were also present in Experiment 2a: 932/941, 1051/1060, 1153/1162, 
1195/1204, 1210/1219, 1566/1575, 1578/1587 and 1712/1721. 
MS and MS/MS of the fractions resulted in the identification of 44 MS ions 
matching to 12 putative ICAT-labelled peptides from twelve proteins (Table 5). 
Triosephosphate isomerase was identified with two peptides. Four of the twelve 
peptides were accepted for quantification and had ratio ranging from 0.0003 to 40.6. 
Fructose-bisphosphate aldolase A showed a ratio near unity. Two other peptides, 
trafficking protein particle complex subunit 1 and LIM and calponin homology domains-
containing protein 1, had a ratio <1 indicating a decrease in the heavy-labelled sample or 
an increase in the light-labelled sample. Von Willebrandfactor A domain-containing 
protein 3A was identified with a ratio of 52.01, indicating an increase in the heavy sample 
or an decrease in the light sample. The remaining peptides, phosphoglycerate kinase, 
triosephosphate isomerase, uncharacterized protein C4orf50, zinc finger protein 502, 
glyceraldehyde-3-phosphate dehydrogenase, mitogen-activated protein kinase kinase 
kinase 3 and ras GTPase-activating protein 1, had a SE of above 0.1 leading to exclusion 
from the quantitation. 
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Figure 23: MS spectra of ICAT labelled peptides from Experiment 2b prior to RP-LC fractionationing. 
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Figure 22: UV trace of the RP separation of ICAT labelled peptides from Experiment 2b using the TEMPO LC-spotter.  
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Table 5: List of identified proteins, accession numbers and determined ratios from Experiment 2b. 
 Protein description Uniprot 
accession 
# 
Score1 Ratio 
Light/ 
Heavy 
Sequence 
1 Phosphoglycerate 
kinase 
B7Z7A9 82 No 
quantificat
ion3 
ACANPAAGSVILLENLR 
2 Triosephosphate 
isomerase 
P60174 35 No 
quantificat
ion3 
VPADTEVVCAPPTAYIDFAR, 
VAHALAEGLGVIACIGEK 
3 Fructose-
bisphosphate 
aldolase A 
H3BMQ8 27 0.932 VNPCIGGVILFHETLYQK 
4 Uncharacterized 
protein C4orf50 
E9PNW5 21 No 
quantificat
ion3 
CSVAQGQALSSLSNGPMLR 
5 Zinc finger protein 
502 
Q8TBZ5 18 No 
quantificat
ion3 
YACEGMKENSPR 
6 Glyceraldehyde-3-
phosphate 
dehydrogenase 
E7EUT5 17 No 
quantificat
ion3 
VPTANVSVVDLTCR 
7 von Willebrand factor 
A domain-containing 
protein 3A 
A6NCI4 17 52.012 VCILLDTSGSMGPYLQQVK 
8 Trafficking protein 
particle complex 
subunit 1 
F8WE24 17 0.00032 CVVLSDPLK 
9 Mitogen-activated 
protein kinase kinase 
kinase 3 
J3KRN4 16 No 
quantificat
ion3 
LQTICMSGTGMR 
10 Ras GTPase-
activating protein 1 
B4DTL2 16 No 
quantificat
ion3 
DLAALHEICVAHSDELR 
11 LIM and calponin 
homology domains-
containing protein 1 
G5EA03 14 0.072 NQGHTEEVKLIVTCNMR 
1 Protein score calculated by Mascot 
2 based on one identified peptide 
3 rejected because the standard error was above the threshold of 0.1 
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3.2.3 Comparison of all ICAT experiments 
The precursor masses of the identified peptides of all ICAT experiments have been 
compared (Table 6). The highlighted matches are glyceraldehyde-3-phosphate 
dehydrogenase (green) and von Willebrand factor A domain-containing protein 3A 
(gray). 
 
Table 6: List of MS ions from identified peptides of the different experiments. Different colors highlighting similar 
MS ions between the experiments. 
Experiment 
No. 1 No. 2a No. 2b 
1347.67 1024.57 1209.326 
1417.681 1126.57 1533.85 
1496.74 1186.49 1627.851 
1529.75 1359.66 1700.904 
1548.77 1399.651 1939.015 
1664.79 1635.8 2128.125 
1700.832 1938.95 2146.083 
1709.865 2142.94 2208.175 
1768.79 2214.942 2267.163 
1784.77 2295.045 2295.199 
1992.97  2362.193 
 
3.2.3.1 Alternative Mascot searches 
The Mascot algorithm searches only for cys-containing heavy and light peptide 
pairs with 9 Da mass differences, when the ICAT quantitation method is selected.  
Alternative searches were therefore performed with the data from the second 
experiment to identify possible peptides that did not contain cys residues. Possibilities 
that were examined included peptides without cys that were retained after avidin 
cleanup, or ICAT peptides without a 9 Da pair that might reflect inability to label a 
completely modified cysteine in one treatment group.  Four different search routines 
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were used; no ICAT, both ICAT reagents as variable modifications, ICAT reagent light as 
fixed modification with ICAT reagent heavy as variable modification and ICAT reagent 
heavy as fixed modification with ICAT reagent light as variable modification. The search 
allowing for both ICAT reagents as variable modifications identified some peptides with 
an ICAT tags in line with the original search. These peptides were identified as 
phosphoglycerate kinase, acidic leucine-rich nuclear phosphoprotein 32 family member B 
and fructose-bisphosphate aldolase. Two peptides from the original search gave 
different matches; the titin peptide (NVDSVVNGTCR, score 19) now matched fructose-
bisphosphate aldolase (PNMVTPGHACTQK, score 2), while the pleckstrin homology 
domain protein (TCFVVLSNGILYQYPDR, score 19) now matched actin 
(DLYANTVLSGGTTMYPGIADR, score 150); both without an ICAT tag. 
The results from the search without ICAT as a modification did not give additional 
information and are not shown. In a further comparison between the different searches 
each precursor mass leading to a protein identification for the quantitative search was 
matched with the peptide sequence and a peptide score from the search with ICAT as a 
variable modification (Tab. 7). A higher peptide score for a peptide without an ICAT 
modification was assumed as an indication of a carry-over of unlabelled peptides. In 
Experiment 2a only one ICAT pair could be fully confirmed (highlighted in green); 
phosphoglycerate kinase. Two peptides fulfilled the requirements to be considered as 
GTX-induced modifications (highlighted in gray): acidic leucine-rich nuclear 
phosphoprotein 32 family member A and von Willebrand factor A domain-containing 
protein 3A. The requirements were the loss of the heavy ICAT partner of the pair, a high 
score for the identified light ICAT-labelled peptide and the presence of the complete ICAT 
pair in Experiment 2b. Cytoplasmic Actin 1 was identified with a high score as an 
unlabelled peptide (highlighted in blue), and therefore might be contamination of the 
avidin-selected sample by a non-cys peptide from this high abundance protein. Three 
peptides were marked as ‘unknown’ (highlighted in orange) because the identification 
score of the labelled peptide was higher than the one for an unlabelled peptide, but the 
ICAT partner was not present either in Experiment 2a or 2b. This was done to 
differentiate them from possible GTX-modifed peptides, because in the case of a cysteine 
modification both ICAT-labelled peptides should be at least present in experiment 2b. 
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This left four ICAT pairs unclassified (not highlighted). Two of these four (1399.6510 m/z 
and 1126.5650 m/z) were identified as a labelled peptide and the matching precursor 
(1391.4681 m/z and 1117.5654) as an unlabelled one, which could indicate an unlabelled 
peptide of the same mass (1391.4681 m/z and 1117.5654) masked the labelled partner or 
the labelled peptide (1399.6510 m/z and 1126.5650 m/z) was misidentified. One of the four 
(1024.9420 m/z) was identified as a labelled peptide missing an ICAT partner but was not 
identified in Experiment 2b. This might be a GTX-targeted protein but the matching 
partner (1033.x m/z) was identified differently in Experiment 2b. The remaining ICAT pair 
(1208.2160 m/z, 1208.2270 m/z and 1199.8373 m/z, 1199.5764 m/z, 1199.5764 m/z) showed 
a positive identification of one ICAT-labelled peptide (1208.2160 m/z, ICAT H) but a 
peptide with a very similar mass was identified differently (1208.2270 m/z). Additionally, 
all three putative ICAT partner (1199.8373 m/z, 1199.5764 m/z, 1199.5764 m/z) were 
identified differently. 
 
  
 
Table 7: Comparative table of precursor masses from Exp. 2a with possible ICAT pair matches, the Mascot score from the quantitative search and a Mascot search with ICAT as 
variable modifications, the light to heavy ratio, the presence in pre and post avidin spectra and in Experiment  2b, the assigned peptide sequence and the matching protein. 
Green indicates a confirmed ICAT pair, gray a possible GTX-induced cys modification, orange an unknown labeling status and blue a possible contamination. The peptide 
sequence is given from the identification with the highest score. In case of the same score the peptide sequence from Mascot search with ICAT as variable modification is given 
in breakets. 
Peptide 
Mass 
possible 
Match 
Score 
(quant) 
Score 
(ICAT 
var) 
L/H present in  peptide sequence Protein 
pre/ 
post 
avidin 
Exp. 2b 
1938.9870 1947.9870 39 (ICAT 
L) 
40 (ICAT L) 2.02 N Y  Y 1 ACANPAAGSVILLENLR Phosphoglycerate kinase 
1947.9772 1938.9772 20 (ICAT 
H) 
- 2.02 N N  Y 1 ACANPAAGSVILLENLR Phosphoglycerate kinase 
1947.9788 1938.9788 - 20 (ICAT H) 2.02 N N  Y 1 ACANPAAGSVILLENLR Phosphoglycerate kinase 
                 
2142.937   32 (ICAT 
L) 
26 (ICAT L) 1.03 N N  Y 3 SLDLFNCEVTNLNDYR Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
  2151.x - - - N N  Y 4 -   
                   
1399.651   19 (ICAT 
H) 
13 (ICAT H) 0.02 N N  Y 2 NVDSVVNGTCR Isoform 5 of Titin 
          
                
1208.216   9 (ICAT H) 9 (cys) - N N Y 1 VLDSPGPCGK  
(LVAKDGSCLFR) 
Isoform 5 of Titin 
1208.227   11 (ICAT 
H) 
22 (no cys) - N N Y 2 VAAGAMEGVLYK Pleckstrin homology domain-
containing family A member 8 
(Fragment) 
  1199.8373 8 (ICAT H) 7 (no cys) - Y N Y 2 GEAGGQGECR Testicular haploid-expressed gene 
protein (Fragment) 
  1199.5764 5 (ICAT L) 10 (no cys) - Y N Y 2 RALSWAAATPR Putative E3 ubiquitin-protein ligase 
4
8 
  
 
Peptide 
Mass 
possible 
Match 
Score 
(quant) 
Score 
(ICAT 
var) 
L/H present in  peptide sequence Protein 
pre/ 
post 
avidin 
Exp. 2b 
UBR7 
  1199.5764 5 (ICAT L) 13 (no cys) - Y N Y 2 SSVMTTEITSK Zinc finger protein 385D 
                
1359.656   19 (ICAT 
H) 
14 (no cys) 0.32 N N Y 2 AMLNISESCR Vacuolar protein sorting-associated 
protein 13B 
  1350.x - - - N N N -   
                
2214.942   19 (ICAT 
L) 
150 (no cys) - N Y Y 2 DLYANTVLSGGTTMYPGIADR Actin, cytoplasmic 1 
  2223.x - - - Y N N -   
                
1024.566   17 (ICAT 
L) 
6 (no cys) 0.90 N  N N GEVSCFR Myotonin-protein kinase 
  1033.x - - - N  N Y 3 -   
                  
1126.565 1117.5654 16 (ICAT 
H) 
16 (no cys) 0.34 N N Y 1 CSGGAGAVLR 
(PSAVSSGPRLR) 
Uncharacterized protein (Fragment) 
1117.648 1126.6477 14(ICAT L) 19 (no cys) - N N Y 4 MATLWGGLLR Transmembrane protein 9B 
                
1635.8   15 (ICAT 
L) 
16 (ICAT L) 1.54 N N Y 1 SMNQAICIPLYR Anaphase-promoting complex 
subunit 4 
  1644.x - - - N N N -   
                
1186.489   15 (ICAT 
H) 
14 (ICAT H) 0.09 N  N Y 1 MPGLSCGGGR Peptidyl-prolyl cis-trans isomerase G 
(Fragment) 
  1177.x - - - N  N N -   
4
9
 
  
 
Peptide 
Mass 
possible 
Match 
Score 
(quant) 
Score 
(ICAT 
var) 
L/H present in  peptide sequence Protein 
pre/ 
post 
avidin 
Exp. 2b 
                   
2295.045   14 (ICAT 
L) 
15 (ICAT L) 40.611 N  Y Y 1 VCILLDTSGSMGPYLQQVK von Willebrand factor A domain-
containing protein 3A 
  2304.x - - - N  N Y 2 -   
5
0 
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The same searches were performed for Experiment 2b (Table 8). Three potential 
ICAT pairs were identified (highlighted in green); phosphoglycerate kinase, 
triosephosphate isomerase and glyceraldehyde-3-phosphate dehydrogenase. Six of the 
nine remaining peptides where identified as labelled peptide but the ICAT partner was 
missing, so they were considered as ‘unknown’ (highlighted in orange) because the 
expected ICAT patner should at least be detected as MS ion. From the three remaining 
peptides, two peptides (2146.0825 m/z and 2295.1987 m/z) were identified with an ICAT 
label but the potential partners (2155.1621 m/z and 2304.1170 m/z) were identified as 
unlabelled peptides. From the remaining peptide (2128.1246 m/z) the putative partner 
(2119.0389 m/z) was identified as a labelled and as an unlabelled peptide with the same 
mascot score. 
  
 
Table 8: Comparative table of precursor masses from Experiment 2b with possible ICAT pair matches, the mascot score from the quantitative search and a mascot search with ICAT as 
variable modifications, the light to heavy ratio, the presence in pre- and post-avidin spectra and in Experiment 2a, the assigned peptide sequence and the matching protein. Green 
indicates a confirmed ICAT pair, and orange an unknown labeling status. The peptide sequence is given from the identification with the highest score. In case of the same score the 
peptide sequence from Mascot search with ICAT as variable modification is given in breakets. 
Peptide 
Mass 
possible 
Match 
Score 
(quant) 
Score 
(ICAT 
var) 
L/H present in peptide sequence Protein 
pre/ 
post 
avidin 
Exp. 2a 
1939.0152 1948.0258 70 (ICAT L) 70 (ICAT L) 1.67 N N Y 1 ACANPAAGSVILLENLR Phosphoglycerate kinase 
1948.0258 1939.0152 7 (ICAT H) 7 (ICAT H) 1.67 N N Y 2 SDLNLTRGVGWTPPGSYK Phosphoglycerate kinase 
                
1987.0510   17 (ICAT H) 17 (ICAT H)   N N N VAHALAEGLGVIACIGEK Triosephosphate isomerase 
  1978.x - -   N N Y 4 -   
                
2362.1932 2371.2309 35 (ICAT L) 35 (ICAT L) 0.06 N N N VPADTEVVCAPPTAYIDFAR Triosephosphate isomerase 
2371.2309 2362.1932 12 (ICAT H) 12 (ICAT H) 0.06 N N N VPADTEVVCAPPTAYIDFAR Triosephosphate isomerase 
                  
2267.2039   27 (ICAT H) 27 (ICAT H) 0.93 N N N VNPCIGGVILFHETLYQK Fructose-bisphosphate aldolase A 
(Fragment) 
  2258.x - - 0.93 N N Y 4 -   
                
2146.0825   21 (ICAT L) 21 (ICAT L) 3.54 N N Y 2 CSVAQGQALSSLSNGPMLR Uncharacterized protein C4orf50 
  2155.1621 7 (ICAT H) 8 (no cys) 3.54 N N Y 3 PMDDDLLKLLLPLMLQVR Mediator of RNA polymerase II 
transcription subunit 12-like protein 
                 
1627.8508   18 (ICAT L) 18 (ICAT L) 1.73 N Y Y 1 YACEGMKENSPR Zinc finger protein 502 
  1636.x - - 1.73 N Y Y 2 -   
                
5
2 
  
 
Peptide 
Mass 
possible 
Match 
Score 
(quant) 
Score 
(ICAT 
var) 
L/H present in peptide sequence Protein 
pre/ 
post 
avidin 
Exp. 2a 
1700.9039 1709.9277 17 (ICAT L) 17 (ICAT L) 0.86 N N Y 1 VPTANVSVVDLTCR Glyceraldehyde-3-phosphate 
dehydrogenase 
1709.9277 1700.9039 11 (ICAT H) 11 (ICAT H) 0.86 Y N Y 3 VPTANVSVVDLTCR Glyceraldehyde-3-phosphate 
dehydrogenase 
                 
2295.1987   17 (ICAT L) 17 (ICAT L) 52.01 N Y Y 1 VCILLDTSGSMGPYLQQVK von Willebrand factor A domain-
containing protein 3A 
  2304.1170 1 (ICAT L) 3 (cys) 52.01 N N N EAVCLGTCPEPEASMSTAIPGLK Isoform 4 of APOBEC1 
complementation factor 
                
1209.3257   17 (ICAT H) 17 (ICAT H) <0.01 N N Y 2 CVVLSDPLK Trafficking protein particle complex 
subunit 10 
  1200.x - - <0.01 N N N -   
                
1533.8504   16 (ICAT H) 16 (ICAT H) 0.35 N N Y 2 LQTICMSGTGMR Mitogen-activated protein kinase 
kinase kinase 
  1524.x - - 0.35 N N N -   
                
2128.1246   16 (ICAT H) 16 (ICAT H) 0.28 N N Y 2 DLAALHEICVAHSDELR Ras GTPase-activating protein 1 
  2119.0389 14 (ICAT L) 14 (no cys) 0.28 N N N PSTMTDKEMESPECMK 
(GNKGVISSVDGISLQGFPSEK) 
tRNA-splicing endonuclease subunit 
Sen2 
                
2208.1749   14 (ICAT H) 14 (ICAT H) 0.07 N N Y 1 NQGHTEEVKLIVTCNMR LIM and calponin homology domains-
containing protein 1 
  2199.x - - 0.07 N N N -   
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4 Discussion 
4.1 Cellular effects of GTX 
4.1.1 Cell viability 
GTX affects cell viability in HL-60 cells with greater effects at 24 h than at 1 or 3 h.  
At 24 h viability was affected even at the lowest tested concentrations of GTX. The 
results from the short exposure times (1 h and 3 h) are likely to be less accurate because 
of direct reduction of MTT to its formazan by GTX. Yoshida et al. (2000) reported oxygen-
dependent reduction of cytochrome c by GTX in isolated neutrophils. They investigated 
whether reduction was mediated by ROS but added catalase or superoxide dismutase 
failed to prevent cytochrome c reduction, indicating that neither H2O2 nor O2
.- were 
involved in the reduction. Apparent reduction of MTT by GTX was only detected at the 
short exposure times and may have been masked by changes in cell viability at 24 h. 
Further studies are needed to explore the exact conditions and mechanisms of the 
reaction between GTX and MTT to fully explain the results.  
HL-60 cells are a promyelocytic leukemic cell line and may therefore be relevant to 
study of the effects of GTX on immune cells. The TC50 of 76 nM after 24 h of treatment 
can be compared with the TC50 for lung epithelial cells (500 μM) and macrophages. 
Alveolar macrophages are more sensitive (TC50 30 nM) to GTX than the HL-60 cells, which 
might be an evolutionary adaption of A. fumigatus as a lung pathogen (Sugui et al., 2007; 
Kwon-Chung and Sugui, 2009; Abad et al., 2010). This may indicate the selectiveness of 
GTX to immune system-related cells. However, the viability of OE4 cells (H-2d-specific 
CD8+ cytotoxic T lymphocyte) is only marginally affected by GTX up to 10 μM, although 
GTX inhibits the cytotoxic activity of these cells at a much lower dose (IC50 of 0.2 μM) 
(Yamada, Kataoka and Nagai, 2000).  
4.1.2 ROS production 
HL-60 cells treated with up to 10 μg/ml GTX did not show increased ROS production 
compared to untreated cells. In HepG2 cells, GTX slightly increased ROS production (Hur 
et al., 2008), while apoptosis in PU5-1.8 macrophages and hepatic stellate cell has been 
related to ROS (Suen et al., 2001; Kweon et al., 2003). This suggests that GTX may act 
through a variety of possible pathways which might be more or less specific. 
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4.1.3 Cell cycle analysis 
This study is one of the first to show that GTX affects the cell cycle of HL-60 cells. At 
a lower concentration (0.1 μg/ml) no effect on the cell cycle was visible, even though 
MTT assays showed decreased viability at the same concentration. An increase in 
concentration to 1 μg/ml GTX caused a strong increase in apoptosis and a G1 arrest. A G1 
block can be induced over many different pathways such as inhibition of 
geranylgeranyltransferase (Miquel et al., 1997), microtubule depolymerisation (Blajeski et 
al., 2002), DNA damage or cyclin inhibition (Resnitzky and Reed, 1995; Woo and Poon, 
2003). 
Sporidesmin showed a similar effect on the cell cycle in non-tumorigenic rat liver 
cells (Jordan and Pedersen, 1986). Here, cells treated with 0.1 μg/ml sporidesmin for 24 h 
showed a blocked entry into S-phase and after 48 h 95% of the cells were in G1 phase. In 
contrast to GTX, sporidesmin did not cause apoptosis at this concentration. 
4.1.4 Summary 
The results using HL-60 cells indicate that production of ROS is not a major effect of 
GTX, suggesting that the alternative hypothesis of direct modification of protein 
cysteines is relevant to this study. 
 
4.2 ICAT-labelling of BSA 
The initial evaluation of ICAT labelling using BSA showed a high rate of labelling and 
a high Mascot score for peptide and protein identification. Protein coverage of 41% was 
achieved in the sample with a one to one labelling ratio, and 45% in the sample with a one 
to four ratio. This was effective labelling when compared to the maximum possible 
coverage of 53% based on theoretical peptides with no missed cleavages. The 0ne to four 
sample had a lower Mascot score, which might be due to decreased labelling at lower 
protein concentrations, but there was higher protein coverage in this sample due to the 
identification of larger peptides. Both samples had a low FDR (1.4% and 0.4%) which 
shows a robust identification of BSA. Both samples showed the expected protein ratios 
but the variation for individual peptides was greater, indicating that a precise 
determination of the protein ratio may require more than one quantified peptide.  
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4.2.1 ICAT mass spectrometry of HL-60 cell extracts 
For the assessment of cysteine modification by GTX an effective concentration was 
needed to get as many modifications as possible, while the cells should not be in an 
apoptotic state that might introduce additional changes among proteins. Therefore, the 
GTX treatment of HL-60 cells was at a relatively high concentration of 1 µg/ml but only 
over three hours to minimise downstream effects of apoptosis. Additionally, a short 
exposure time was used to minimize protein synthesis following the GTX treatment 
which would influence the protein ratios independent of cysteine modifications. DMEM 
media was chosen because it did not contain GSH which possibly would have interfered 
with the experiment.  
ICAT was expected to be a suitable method for detection of proteins that were 
modified by reaction of cysteine with GTX as GTX is expected to only react with 
accessible surface thiol groups on proteins.  
4.2.1.1 ICAT Experiment One: Comparison of GTX-exposed with control cell extracts 
The analysis of the first ICAT labelling led to the identification of eight proteins, six 
of them with a measured L/H ratio and two without (Table 3). The identified proteins had 
Mascot scores ranging from 25 to 169 based on detected labelled peptides. All proteins 
were identified based on one matched peptide, except for peptidyl-prolyl cis-trans 
isomerase which was matched with two peptides. An additional Mascot search (not 
shown) supported the identification of all proteins with the exception of isoform 4 of 
protein sidekick-2, which was identified with a marginally lower score of 23 as olfactory 
receptor 1L1. Three of the eight proteins were identified with L/H ratio >1, one with a ratio 
of approximately 1 and two with a ratio <1, while two proteins were not quantified. None 
of the identified proteins were one of the already known targets of GTX: ADH, GRx, CK or 
FTase. This is likely due to the relative low abundance of these proteins. The proteins 
with an indicated decrease following GTX treatment were tubulin, glyceraldehyde-3-
phosphate dehydrogenase and peptidyl-propyl cis-trans isomerase. This suggests that 
these three proteins are targeted by GTX resulting in a modification of the susceptible 
cysteine that prevented ICAT labelling leading to a decreased intensity in the heavy 
labelled, GTX-treated, sample. 
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Tubulin was detected with the highest ratio, suggesting it as predominant target 
for GTX, but this might also be due to the high abundance of tubulin. Tubulin has been 
reported to have a reactive cysteine at position 12, 239 and 303 (Kim, Pannell and Sackett, 
2004; Antony et al., 2014). Cysteine 12 was identified to be modified by GTX and is known 
to be a part of guanosine triphosphate (GTP) binding site (Luduena and Roach, 1991). A 
blockage of GTP binding would lead to tubulin depolymerisation (Heald and Nogales, 
2002). Tubulin depolymerisation is associated with mitotic cell arrest (Blajeski et al., 2002) 
which is in contrast with the findings of the cell cycle analysis as GTX caused G1 arrest.  
Glyceraldehyde-3-phosphate dehydrogenase has been reported to have a reactive 
cysteine at position 151 (Perham, 1969; Banas, Banas and Wolny, 1976), but the ICAT 
labelled cysteine was at position 247. This suggests that cysteine 247 is also a reactive 
cysteine but the impact of its modification is yet to be determined. 
Peptidyl-propyl cis-trans isomerase has four cysteinyl residues from which one 
(cysteine 62) was detected as target for GTX. None of the cysteines seems to have an 
essential function (Liu et al., 1990). But a different peptidyl-propyl cis-trans isomerase, 
cyclophilin D, seems to be affected in function by GTX binding (Wright et al., 2001). 
Serum albumin and heterogeneous nuclear ribonucleoprotein A1 showed a ratio 
indicating a higher abundance in the GTX-treated sample than in the control. An 
explanation could be increased protein synthesis following GTX treatment, which is 
unlikely because of the short exposure time, or that GTX, possibly intracellular GTX 
dithiol, acted as a reducing agent and reduced the disulfides into thiols rendering them 
accessible for ICAT labelling. This would then raise the questions, why are only these two 
proteins affected and are all ratios shifted towards the heavy label? 
In the monitoring step prior to LC fractionation, ten putative ICAT pairs could be 
identified from which none could be matched to a peptide sequence with a reasonable 
Mascot score later in the MS/MS analysis (Fig. 17). Four pairs were not identified because 
their mass after cleavage was below the set mass detection minimum of 700 m/z. Four of 
the putative ICAT pairs with a mass above 1380.34 m/z were identified as MS ions but 
could not be matched to a peptide sequence. The remaining pair was not present as MS 
ions. Detection of these additional apparent ICAT pairs by direct MALDI of the avidin-
 62 
 
captured extract indicated that only a subset of the ICAT-labelled peptides was detected 
during analysis of the TEMPO fractions.  
4.2.1.2 ICAT Experiment Two (2a): Comparison of GTX-exposed with control cell extracts 
Ten potential ICAT-labelled proteins were identified in the second comparison of 
HL-60 proteins from GTX and control cells, nine with one matching peptide, plus titin 
which was identified from two peptides (Table 4). From these eleven peptides only two 
were quantified as ICAT pairs in the Mascot analysis. The ratio of myotonin-protein kinase 
was 0.9, near unity, but von Willebrand factor A domain-containing protein 3A ratio was 
approximately 40 indicating a higher abundance in the GTX-treated sample than in the 
control. None of the proteins identified in Experiment One was re-identified in this 
experiment, but two proteins were from the same protein family (peptidyl-prolyl cis-
trans isomerase from Experiment One and peptidyl-prolyl cis-trans isomerase G from 
Experiment Two). Increased labelling of the von Willebrand factor protein might be due 
to GTX dithiol mediated reduction of a susceptible cysteine in this protein.  
Subsequent Mascot searches (Table 7) using ICAT as a variable modification 
supported the identification of only nine of the ten proteins, as the pleckstrin homology 
domain-protein  was alternatively identified as actin without an ICAT label at a much 
greater score (150 compared to 19). To examine why only two of the proteins were 
quantified, a search for 9 Da putative ICAT pairs showed that both ICAT-labelled peptides 
were identified only for phosphoglycerate kinase. However, other possible proteins 
could be identified in which the heavy ICAT-labelled peptide was not present in 
Experiment Two but was detected in the control labelling experiment, Experiment Three 
(2b). These proteins, acidic leucine-rich nuclear phosphoprotein 32 family member A and 
von Willebrand factor A domain-containing protein 3A, were therefor considered as 
putative targets of GTX due to the complete loss of the heavy label. This contrasts with 
the ratio determined for von Willebrand factor A domain-containing protein 3A. Three 
other proteins, vacuolar protein sorting-associated protein 13B, anaphase-promoting 
complex subunit 4 and peptidyl-prolyl cis-trans isomerase G (Fragment) were identified in 
both experiments (Two and Three) without a heavy label. 
Eight putative ICAT pairs were detected by direct MALDI of the avidin-captured 
peptides prior to LC (Fig. 20), but only one matched a protein that was identified from 
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the LC fractions: the putative ICAT pair at m/z 2040/2049 matched to vacuolar protein 
sorting-associated protein 13B. However, the peptide leading to the identification of the 
protein was detected with only a heavy ICAT label. This could either mean that the 
peptide was falsely identified or that there is another peptide with the same m/z 
containing a light ICAT label. The results again suggested that more ICAT pairs were 
present than those identified after offline LC MALDI, and there were many unidentified 
MS ions. 
4.2.1.3 ICAT Experiment Three (2b): Comparison of light and heavy labelled control cell 
extracts 
Experiment Three was planned to evaluate the ICAT procedure using light and 
heavy labelling of a control cell extract. It was carried out and processed as the same 
time as Experiment Two using the same batch of ICAT reagents. 
Eleven proteins were identified based on twelve peptides. Triosephosphate 
isomerase was identified by two matching peptides (Table 5). Four of the eleven proteins 
were quantified: one with a label ratio near unity (fructose-bisphosphate aldolase A), two 
with higher abundance in the heavy-labeled sample (trafficking protein particle complex 
subunit 1 and LIM and calponin homology domains-containing protein 1), and one with a 
higher abundance in the heavy labeled sample (von Willebrand factor A domain-
containing protein 3A). The presence of von Willebrand factor A domain-containing 
protein 3A in the control experiments with a ratio similar to Experiment Two contradicts 
the former suggestion that change was due to GTX-mediated reduction. The second high 
ratio variation raises additional questions about the basis of detected change. 
The additional Mascot searches supported the identification of three proteins by 
identifying both ICAT-labelled peptides (Table 8). These three were phosphoglycerate 
kinase, triosephosphate isomerase (peptide VPADTEVVCAPPTAYIDFAR) and 
glyceraldehyde-3-phosphate dehydrogenase. From the other proteins only one of the 
ICAT-labelled peptides was identified. The other putative peptide was either not present 
or identified as a peptide with a different peptide sequence matching a different protein. 
The previously identified putative ICAT pairs from the MS prior to LC  
(Fig. 23) did not match with the identified peptides. All of the putative pairs were present 
in the following MS/MS analysis as MS ions, but no peptide sequence could be identified. 
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4.2.2 ICAT performance 
The number of MS ions matched to a peptide sequence and subsequent protein 
identification was low in all three HL-60 experiments compared to the BSA experiments. 
From the BSA samples 661 and 294 MS ions (1-to-1 sample and 1-to-4 sample, respectively) 
were matched to a peptide sequence, while only 56 to 35 MS ions of the HL-60 ICAT 
samples were matched to peptide sequences. One explanation could be the higher 
complexity of the HL-60 samples resulting in a lower amount of each protein for 
labelling. Exclusion of the standard reduction step in the ICAT protocol may also have 
affected labelling. Although it is necessary to exclude reduction for detection of modified 
cysteines, the peptide pool is decreased from all cys-containing peptides to only reactive 
and accessible cys-containing sequences. Additionally, it appeared that some non cys-
containing and unlabelled cys-containig peptides were retained after avidin capture of 
labelled cell extracts suggesting contamination possibly due to high abundance proteins 
including actin. 
Potential optimization steps include an additional fractionation using the strong ion 
exchange column, and an increased initial sample amount to compensate for the 
decreased possible peptide set. Prefractionation, by decreasing complexity, would 
increase resolution of the sample which would be beneficial for low abundance proteins 
and may assist purification as a lower protein amount would be loaded on each avidin 
column. This might also help reduce contamination with unlabelled high abundance 
proteins. An increased sample amount might also increase the MS/MS quality as more of 
each specific peptide would be present, but an increase needs to be carefully considered 
as the ICAT reagent is designed to label a certain amount of protein. An excess of 
cysteine compared to ICAT reagent may result in sub-minimal labelling that could 
compromise further quantitative analysis. 
 
4.2.3 Summary 
The results of this study give new insights into the effects of GTX on HL-60 cells. 
GTX affects the cells at a relative low dose of 0.02 μg/ml. The effects may predominantly 
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be due to covalent modification instead of ROS production. GTX affects the cell cycle by 
blocking the entry into the S-phase, but only at doses high enough to induce apoptosis.  
ICAT labelling led to the identification of three putative cellular targets of GTX: 
tubulin, glyceraldehyde-3-phosphate dehydrogenase and peptidyl-prolyl cis-trans 
isomerase. ICAT was therefore apparently capable of detecting cysteine modification in a 
complex sample but further optimization is needed to improve the detection rate, 
quantitation and reproducibility.  
Suggested further work includes: 
 Use of optimized ICAT methods for labelling and workup of cell extracts 
 ICAT labelling of unreduced BSA to evaluate the effects compared to reduced 
BSA  
 ICAT labelling of BSA treated with GTX to identify possible reactive cysteines 
  Characterization by MS/MS of the possible cysteine modifications of tubulin, 
glyceraldehyde-3-phosphate dehydrogenase and peptidyl-propyl cis-trans 
isomerase, either using cell extracts or by exposure of purified proteins to GTX  
  Investigation of the potential effects of GTX on destabilization of tubulin in vitro 
and in cultured cells. 
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APPENDICES 
Appendix A 
 
Flow table of RP-LC from BSA samples and Experiment 1. 
Time (min) % A % B 
0 98 2 
40 20 80 
44 20 80 
48 98 2 
56 98 2 
 
 
 
Flow table of RP-LC from Experiment 2a and 2b. 
Time (min) % A % B 
0 98 2 
5 80 20 
35 50 50 
40 20 80 
44 20 80 
48 98 2 
56 98 2 
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Appendix B 
 
List of reference masses for internal MS calibration.  
m/z monoisotopic Description 
757.4 Bradykinin fragment 1-7 
1046.542 Angiotensin II (human) 
1533.858 P14R (synthetic peptide) 
2465.199 
ACTH fragment 18-39 
(human) 
3494.651 
Insulin oxidized B chain 
(bovine) 
 
List of reference masses for internal MS/MS calibration.  
m/z monoisotopic Description 
157.109 b1 
254.162 b2 
353.23 b3 
481.325 b4 
580.393 b5 
743.457 b6 
840.51 b7 
954.552 b8 
1011.574 b9 
1082.611 b10 
1211.654 b11 
1326.681 b12 
1542.755 b14 
1613.792 b15 
1742.835 b16 
1813.872 b17 
1960.94 b18 
2057.993 b19 
2112.977 y19 
2171.077 b20 
2212.045 y20 
2300.12 b21 
2309.098 y21 
2447.188 b22 
2465.199 y22 
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